Page last updated: 2024-09-04

febuxostat and Gout

febuxostat has been researched along with Gout in 367 studies

Research

Studies (367)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (0.54)	18.2507
2000's	35 (9.54)	29.6817
2010's	215 (58.58)	24.3611
2020's	115 (31.34)	2.80

Authors

Authors	Studies
Li, H; Sun, J; Wang, M; Wen, C; Xie, Z; Zhang, M; Zhang, Y; Zhao, T	1
Xu, C	2
Ford, I; MacDonald, TM; Mackenzie, IS; Nuki, G; Robertson, M	1
Singh, JA	8
Downie, L; Riches, PL; Thomson, C	1
Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Tsujita, K; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N	1
Geng, H; Jia, E; Lin, F; Liu, S; Wang, Y; Zhang, J; Zhong, L; Zhu, H	1
Lee, YH; Song, GG	1
Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Konishi, M; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Tsujita, K; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N	1
Afinogenova, Y; Danve, A; Neogi, T	1
Billington, K; Bursill, D; Dalbeth, N; Doyle, AJ; Gamble, GD; Horne, A; Latto, K; Mihov, B; Murdoch, R; Narang, R; Parshu Ram, T; Stamp, LK; Tan, P	1
Chen, S; Deng, W; Huang, Q; Huang, Y; Huang, Z; Lee, PY; Li, T; Zheng, S	1
Blake, KEG; Saag, JL; Saag, KG	1
Chang, TI; Han, SH; Jhee, JH; Joo, YS; Kang, SW; Kim, HW; Kim, JY; Park, JT; Roh, YH; Yoo, TH; Yun, HR	1
Fairbanks, L; Gibson, T; Löffler, W	1
Calogiuri, G; Congedo, M; Foti, C; Macchia, L; Nettism, E; Vacca, A	1
Becker, MA; Borer, JS; Castillo, M; Gorelick, PB; Gunawardhana, L; Hunt, B; Saag, KG; Whelton, A; White, WB	2
Gruber, F; Kossmeier, M; Leitner, S; Litschauer, B; Reichardt, B; Sibinovic, S; Weisshaar, S; Wolzt, M	1
Deng, JH; Zhang, JX	1
Cheng, R; Gao, L; Wang, B	1
Kawada, T	2
Choi, J; Ghang, BZ; Kim, J; Lee, JS; Yoo, B	1
Chen, J; Hu, Y; Jiang, B; Lou, H; Ruan, Z; Xu, Y; Yang, D	1
Chen, Y; Cheng, X; Cui, L; Dalbeth, N; He, Y; Hu, S; Ji, A; Li, C; Li, H; Liu, Z; Lu, J; Ma, L; Qi, H; Ran, Z; Sun, M; Terkeltaub, R; Wang, C; Xue, X; Yan, F; Yu, Q; Yuan, X	1
Abuhelwa, AY; Day, RO; Duong, JK; Foster, D; Graham, GG; Kamel, B; Pile, KD; Williams, KM	1
Bittleman, D; Coras, R; Dadpey, B; Guma, M; Hamilton, B; Lauro, K; Liu-Bryan, R; Mikuls, TR; Quehenberger, O; Reilly, SM; Terkeltaub, R; Thorisdottir, H	1
Deng, JH; Zhang, JX; Zhong, GW	1
Choi, SR; Ha, YJ; Han, M; Kang, EH; Lee, EB; Lee, YJ; Shin, A	1
Steurer, J	1
Allada, R; Ann, EYC; Ganesan, T; Ghosal, S; Kwok, J; Muthudoss, P; Omar, MF; See, HH; Shahnawaz, SS; Voguri, RS	1
Cao, Y; Deng, Y; Jiang, X; Li, C; Li, X; Lin, P; Ma, Y; Sun, F; Tao, Y; Wang, C; Yu, Q; Zhu, Y	1
Cheng, H; Hou, X; Li, X; Nan, G; Ren, L; Tian, J; Xiao, Z; Yan, D; Yang, Y; Ye, F	1
Meng, J; Xu, C	1
Iguchi, T; Ishiguro, C; Kajiyama, K; Kimura, R; Nakazato, Y; Oniyama, Y; Sawada, S; Shida, H; Uyama, Y	1
Ghang, B; Jeong, W; Kim, J; Lee, J	1
Choi, E; Jeong, H; Kim, B; Suh, A; Yoo, M	1
Cao, B; Yang, N	1
Chen, M; Cui, R; Dai, SM; Du, Y; Tong, Q; Wang, SI; Wei, JC	1
Haydar, SMA; Murray, N; Nicolaou, S; Ouellette, H; Saffarzadeh, M; Shojania, K	1
Kotake, K; Mitsuboshi, S	1
Kuo, CF; Li, PR; Liu, JR; See, LC; Tsai, PH	1
Lee, J; Min, J; Saag, KG; Shin, S; Terkeltaub, R	1
Domingues, V; Gorlitsky, B; Guedes, M; Karaboyas, A; LaMoreaux, B; Lew, S; Marder, B; Pecoits-Filho, R; Rivara, MB; Robinson, B; Zhao, J	1
Chen, X; Feng Li, H; Hong, Y; Li, Z; Wang, G; Wang, Y; Wu, W; Zhang, X; Zhou, C; Zhou, D	1
Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kohagura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Tsujita, K; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N	1
Du, B; Lin, T; Mu, L; Shang, Q; Wang, X; Zhang, L	1
Abdel Moneim, AE; Daabees, HG; Elagawany, M; Rashad, AY; Rostom, SAF; Shahin, M	1
Do, JY; Kang, SH; Kim, BY; Kim, GO; Son, EJ	1
Kim, AR; Lee, SG; So, MW	1
Dalbeth, N; Narang, RK	1
Hisatome, I; Kondoh, H; Matsumura, Y; Ohtahara, A; Takeda, T; Teramoto, K	1
Cheng, X; Cui, L; He, Y; Ji, A; Li, C; Li, H; Liang, N; Ma, L; Sun, M; Sun, R; Sun, W; Wang, C; Wu, X; Xu, T; Xue, X; Yuan, X; Zhang, H	1
Bechman, K; Galloway, JB; Lanyon, P; Russell, MD; Rutherford, AI; Subesinghe, S; Yates, M	1
Chen, JS; Chiou, MJ; Chung, TT; Hsieh, AH; Kuo, CF; Lan, WC; Luo, SF; Tseng, WY; Wang, LC; Yu, KH	1
Batteux, B; Gras-Champel, V; Laville, SM; Liabeuf, S; Marienne, J; Masmoudi, K; Rey, A	1
Ahn, SM; Ghang, B; Kim, J; Kim, YG; Lee, CK; Yoo, B	1
Kuriyama, S	1
Cheung, PP; Chua, CKT; Lim, AYN; Santosa, A; Teng, GG	1
Abhishek, A	1
Cheung, BMY; Ho, J; Hung, JKF; Ju, C; Lai, JCL; Lai, RWC; Li, KHC; Liu, T; Liu, Y; Tam, LS; Tse, G; Tsoi, MF; Wong, ICK	1
Hoshide, S; Kabutoya, T; Kario, K; Ueno, H	1
Furuno, K; Hosoya, T; Kanda, S	1
Azar, A; Koenig, D; Royer, C	1
Choi, SW; Choi, SY; Lee, S; Lim, DH; Oh, JS; So, MW	1
Genç, H; Mülkoğlu, C; Nacır, B	1
Abe, T; Ito, S; Kikuchi, K; Kudo, M; Maeda, Y; Matsuhashi, T; Mishima, E; Mori, T; Nakajima, Y; Oikawa, Y; Sohara, E; Suzuki, T; Toyohara, T; Uchida, S	1
Alten, R; Mischkewitz, M; Nitschmann, S	1
Borghi, C; Johnson, RJ; Kuwabara, M	1
Cheng, X; Li, C; Li, H; Lu, J; Sun, R; Xin, Y	1
Gu, SW; Huang, YY; Jiang, ZY; Ye, Z; Zhao, L	1
Carland, JE; Day, RO; Graham, GG; Kamel, B; Liu, Z; Pile, KD; Stocker, SL; Williams, KM	1
Abeles, AM; Bae, SS; Brignardello-Petersen, R; Dalbeth, N; Danve, A; FitzGerald, JD; Gelber, AC; Guyatt, G; Harrold, LR; Khanna, D; Khanna, PP; Kim, SC; King, C; Lenert, A; Levy, G; Libbey, C; Mikuls, T; Mount, D; Neogi, T; Pillinger, MH; Poon, S; Qasim, A; Rosenthal, A; Sehra, ST; Sharma, TSK; Sims, JE; Singh, JA; Smith, BJ; Toprover, M; Turgunbaev, M; Turner, AS; Wenger, NS; Zeng, L; Zhang, MA	1
Lin, CJ; Lin, JY; Shi, Y; Sun, SS; Zhang, DH	1
Brown, JN; Hu, AM	1
Ahn, E; Kim, A; Kim, GT; Kim, Y; Lee, SG; So, MW	1
Andraca-Carrera, E; Hsueh, YH; Mistry, K; Neuner, R; Nikolov, NP; Seymour, S	1
Hsu, PK; Lee, YH; Wei, JCC	1
Chung, WH; Ma, KS; Wei, JC	1
Nuki, G; Riches, P	1
Eliseev, MS; Novikova, AM	1
Jatuworapruk, K; Lertnawapan, R	1
Andrés, M; Blanco Cáceres, BA; Calvo-Aranda, E; Diaz-Torne, C; Pascual, E; Pérez Ruiz, F; Prada-Ojeda, A; Quilis, N; Sivera, F; Vela, P	1
Bang, D; Curovic, F; Igel, TF; Katz, SD; Krasnokutsky, S; Lazaro, D; Oh, C; Pike, VC; Pillinger, MH; Romero, AG; Shah, B; Toprover, M	1
Fan, M; Gu, J; Li, X; Liu, J; Schlesinger, N; Wu, X; Zhao, B	1
Schattner, A	1
Penserga, EG; Quilisadio, JEC; Salido, EO	1
Deng, H; Jin, HM; Tong, JD; Yang, XH; Zhang, BL	1
Johansson, S; Leander, J; Rekić, D	1
Desai, RJ; Kim, E; Kim, SC; Lii, J; Neogi, T	1
Clebak, KT; Croad, JR; Morrison, A	1
Bardin, T; Richette, P	2
De Caterina, R; Findlay, E; Ford, I; Hallas, J; Hawkey, CJ; MacDonald, TM; Mackenzie, IS; McMurray, JJV; Nuki, G; Perez-Ruiz, F; Ralston, SH; Robertson, M; Walters, M; Webster, J	1
Onuora, S	1
Pan, R; Xu, Y; Zhang, Y; Zhao, Y	1
Fan, B; Li, X; Zhang, P	1
Hill-McManus, D; Hughes, DA	1
Bahrudin, U; Hisatome, I; Kuwabara, M; Li, P; Maharani, N; Mahati, E; Miake, J; Ninomiya, H; Taufiq, F; Utami, SB	1
Bandyopadhyay, D; Deedwania, P; Fonarow, GC; Ghosh, RK; Gupta, M; Hajra, A; Kaul, S; Klein, A; Lavie, CJ; Mamas, M; Roddy, E	1
Choi, HK; Solomon, DH; Yoshida, K	1
Choi, HK; Dalbeth, N; Neogi, T; Stamp, LK; Terkeltaub, R	1
Cui, X; Geng, H; Jia, E; Jiang, Y; Li, B; Ma, W; Qiu, X; Wei, J; Xiao, M; Xiao, Y; Xie, J; Yao, X; Zhang, J; Zhang, Y; Zhong, L	1
Borghi, C; Desideri, G; Gerritsen, M; Giannattasio, C; Nurmohamed, MT; Rajzer, M; Tausche, AK	1
Estiverne, C; Mount, DB	1
Tausche, AK	1
Desai, RJ; Kim, E; Kim, SC; Liu, J; Pawar, A	1
Ahn, SM; Hong, S; Kim, YG; Lee, CK; Oh, JS; Yoo, B	1
Becce, F; Budzik, JF; Ducoulombier, V; Lefebvre, A; Pascart, T	1
Chen, W; Jin, Z; Wu, M; Zhang, H; Zhang, W; Zhao, D	1
Choudhary, D; Joshi, G; Kumar, S; Sharma, N	1
de Jong, ICA; Rongen, GA; van der Pol, KH; van Herwaarden, N	1
Hosoya, T; Ishikawa, T; Takahashi, T; Taniguchi, T	1
Cheng, R; Gao, L; Lu, Y; Pan, Y; Wang, B	1
Bombardier, C; Edwards, CJ; Pardo Pardo, J; Sriranganathan, MK; Vinik, O	1
Pope, JE; Zhang, T	1
Deeks, ED	1
Neogi, T; Vargas-Santos, AB	1
Hira, D; Ikeda, Y; Katsube, Y; Koide, H; Minegaki, T; Morita, SY; Nishiguchi, K; Terada, T; Tsujimoto, M; Uzu, T	1
Cleveland, JD; Singh, JA	4
Adler, S; Baumgartner, S; Bhakta, N; Dalbeth, N; Fung, M; Jones, G; Khanna, D; Kopicko, J; Perez-Ruiz, F; Storgard, C; Terkeltaub, R	1
Alarid-Escudero, F; Choi, HK; Jalal, H; Jutkowitz, E; Kuntz, KM	1
Kim, JW; Kwak, SG; Park, SH	1
Hill-McManus, D; Hughes, D; Lane, S; Marshall, S; Soto, E	2
Choi, HK; Dalbeth, N; Gunawardhana, L; Hunt, B; MacDonald, PA; Palmer, WE; Saag, KG; Thienel, U	1
Cimmino, MA; Cutolo, M; Perez-Ruiz, F	1
Fujimori, S; Hidaka, Y; Ide, Y; Inoue, K; Kim, H; Sugimoto, M; Tamaki, S; Taniguchi, A; Yamamoto, T; Yamanaka, H	1
Case, R; Jester, G; Wentworth, B	1
Aschenbrenner, DS	2
Kuehn, BM	1
Lioté, F; Pascart, T	1
Basile, M; Cicchetti, A; Drago, C; Rolli, FR; Ruggeri, M	1
Brittan, K; Brophy, M; Davis-Karim, A; Henrie, AM; Mikuls, TR; Neogi, T; Newcomb, J; O'Dell, JR; Palevsky, PM; Pillinger, MH; Pittman, D; Taylor, TH; Timilsina, S; Wu, H	1
Cheng, H; Liu, J; Liu, W; Yan, D; Zhang, Y; Zuo, X	1
McHugh, J	1
Janssen, CA; Krol, M; Oude Voshaar, MAH; van de Laar, MAFJ; Vonkeman, HE	1
Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Saag, K; Whelton, A	1
Ahn, E; Lee, S; So, MW	1
Gillen, M; Hall, J; Ito, Y; Liu, S; Shen, Z; Shiramoto, M; Yamamoto, A; Yan, X	1
Choi, H; Dalbeth, N; Neogi, T; Stamp, L; Terkeltaub, R	3
Tian, JY; Xiao, ZY; Yan, DA; Ye, F; Zhang, L	1
Desai, RJ; Kang, EH; Kim, SC; Liu, J; Neogi, T; Solomon, DH; Zhang, M	1
Dalbeth, N; Robinson, PC	2
Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A	1
Müller-Wieland, D; Nitschmann, S	1
Chen, X; Gu, B; Li, C; Qian, K; Ren, Q; Shen, M; Su, D; Wang, X; Xu, W; Yang, L; Yuan, H; Zhang, J	1
Wang, S	1
Jansen, TL; Perez-Ruiz, F; Richette, P; Tausche, AK	1
Li, C; Wu, X	1
Kuwabara, M	2
Gunawardhana, L; White, WB	1
Bhattacharyya, S; Macklin, EA; Schwarzschild, MA	1
Bartsch, LA; Ortiz, A; Perez-Gomez, MV	1
Lundberg, JO; Montenegro, MF; Weitzberg, E	1
White, WB	1
Robinson, PC	1
Hong, S; Kim, YG; Kwon, OC; Lee, CK; Lee, JS; Lee, SS; Oh, JS; Won, J; Yoo, B	1
Fields, TR	1
Badve, SV; Johnson, DW; Tiku, A	1
Jansen, TLTA; Janssen, M	1
Hao, YJ; Ji, LL; Zhang, ZL	1
Dalbeth, N; Merriman, T; Miner, JN; Stamp, LK; Topless, R	1
Baumgartner, S; Dalbeth, N; Fung, M; Jones, G; Khanna, D; Perez-Ruiz, F; Terkeltaub, R	1
Chen-Xu, M; Choi, HK; Pillinger, MH; Rai, SK; Yokose, C	1
Abeles, AM; Pillinger, MH	1
Chao, PH; Chen, WW; Hsiao, FY; Huang, WI; Lin, CW	1
Chang, CJ; Chang, YC; Chen, CB; Chen, CH; Chen, SM; Chen, WT; Chi, CC; Chung, WH; Hsu, LA; Hung, SI; Lin, KM; Lin, YJ; Lu, CW; Pan, RY; Su, SC; Wang, CW; Wu, YJ; Yu, KH	1
Flynn, RWV; MacDonald, TM; Mackenzie, IS; Rogers, A	1
Gupta, MK; Singh, JA	1
Borghi, C; Mancia, G; Narkiewicz, K	1
Chen, JR; Chen, SL; Yang, SW	1
Ješina, P; Pavelcova, K; Pavelka, K; Pavlikova, M; Stiburkova, B	1
Kim, JM; Kim, SH; Lee, SY; Son, CN	1
Hill-McManus, D; Hughes, DA; Marshall, S; Soto, E	1
Bubb, MR	1
Choi, HK; Kang, EH; Kim, SC; Lee, EB; Lee, YJ; Shin, A; Song, YW	1
Mankad, R	1
Hsieh, SC; Lin, FJ; Lin, LY; Shen, LJ; Su, CY	1
Tana, T; Vadas, P	1
Deng, JX; Jie, LG; Qu, Y; Wu, J; Yu, QH; Zhang, YP	1
Kang, EH; Kim, SC	1
Araujo, E; Baraf, HSB; Bayat, S; Cavallaro, A; Ellmann, H; Kleyer, A; Lell, M; Manger, B; Rech, J; Schenker, H; Schett, G; Simon, D; Tascilar, K	1
Chang, WC; Chen, TC; Hsu, FS; Hwang, JJ; Lee, CC; Liu, CW; Lo, C; Shau, WY; Wang, ML	1
Johnson, TA; Kamatani, N; Kuwabara, M	1
Bianchi, G; Borghi, C; Bortoluzzi, A; Cimmino, MA; D'Avola, GM; Desideri, G; Di Giacinto, G; Favero, M; Govoni, M; Grassi, W; Lombardi, A; Manara, M; Marangella, M; Matucci Cerinic, M; Medea, G; Minisola, G; Prevete, I; Punzi, L; Ramonda, R; Scirè, CA; Spadaro, A	1
Becker, MA; Hunt, BJ; Jackson, RL; MacDonald, PA	1
Beard, SM; Nuki, G; Pearson, IV; von Scheele, BG	1
Franklin, JM; Kim, SC; Liu, J; Schmidt, BM; Schneeweiss, S; Solomon, DH	1
Aringer, M; Bielitz, C; Christoph, M; Forkmann, M; Kopprasch, S; Richter, U; Tausche, AK; Wunderlich, C	1
Dhakad, U; Dhaon, P; Wakhlu, A	1
Bakris, GL; Doghramji, PP; Keenan, RT; Silber, SH	1
Ehteshami-Afshar, A; Faruque, LI; Homik, J; Tjosvold, L; Tonelli, M; Wiebe, N	1
Stamp, LK	2
Bao, C; Du, H; Gu, J; Huang, A; Huang, X; Jiang, L; Li, J; Li, X; Li, Z; Liu, Y; Zhang, Y; Zhang, Z; Zhao, D; Zhu, P; Zuo, X	1
Baumgartner, S; Fleischmann, R; Hingorani, V; Kerr, B; Manhard, K; Miner, JN; Polvent, E; Quart, B; Shen, Z; Suster, M; Yeh, LT	1
Bae, EJ; Chang, SH; Cho, HS; Jang, HN; Kang, Y; Kim, MJ; Park, DJ; Yun, S	1
Akhras, KS; Hatoum, H; Khanna, D; Khanna, P; Lin, SJ; Shiozawa, A	1
Bocale, R; Desideri, G; Ferri, C; Grassi, D; Pontremoli, R	1
Becker, MA; Chaichian, Y; Chohan, S	1
Edwards, NL; So, A	1
Banse, C; Fardellone, P; Paccou, J	1
Bardelli, M; Cantarini, L; Galeazzi, M; Rigante, D; Vitale, A	1
Jansen, TL	1
Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W	1
Mounsey, A; Tillett, J; White, S	1
De Caterina, R; Findlay, E; Ford, I; Hallas, J; Hawkey, CJ; Jennings, CG; MacDonald, TM; Mackenzie, IS; McMurray, J; Nuki, G; Perez Ruiz, F; Ralston, S; Walters, M; Webster, J	1
Kim, HA; Seo, YI; Song, YW	1
Hayashi, H; Hayashi, T; Hikosaka, S; Mizuno, T; Murase, M; Nagamatsu, T; Shimabukuro, Y; Takahashi, K; Yamada, S; Yuzawa, Y	1
Abdi-Ali, L; Benucci, M; Cera, I; Rossini, M; Sacco, S; Saviola, G	1
Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R	1
Choi, HK; Jutkowitz, E; Kuntz, KM; Pizzi, LT	1
Bennett, K; McGowan, B; Silke, C; Whelan, B	1
Bridgeman, MB; Chavez, B	1
Bottorff, MB; Gandhi, PK; Gentry, WM; Ma, Q	1
Frampton, JE	1
Flipo, RN; Patrikos, DK; Richette, P	1
Li, L; Lu, W; Sun, Y; Zhou, TY	1
Akhras, KS; Shiozawa, A; Singh, JA	1
Chen, S; Ji, H; Ji, Q; Lin, J; Liu, B; Liu, H; Liu, P; Liu, X; Lu, Y; Ming, J; Peng, Y; Wang, J; Wang, Y; Xu, S; Zhang, Y	1
Hu, SX; Lei, XM; Shen, GF; Ye, C; Yu, F; Yu, YK; Zhang, ST	1
Dalbeth, N; Stamp, LK	1
Aniel-Quiroga, MA; Atxotegi, J; Chinchilla, SP; Herrero-Beites, AM; Perez-Ruiz, F; Urionagüena, I	1
Chen, CB; Chen, CH; Chen, WL; Chen, YA; Cheng, CY; Chou, HY; Kuo, KL; Ng, CY	1
Gahn, JC; Mitri, G; Shiozawa, A; Smolen, LJ	2
Altan, A; Bancroft, T; Shiozawa, A; Singh, JA	1
Bardin, T; Chalès, G; Clerson, P; Delayen, A; Flipo, RM; Korng Ea, H; Pascart, T; Roujeau, JC	1
Chen, CJ; Chen, DY; Hsu, PN; Lai, JH; Lin, HY; Yu, KH	1
Reuss-Borst, MA	1
Carcedo, D; Díaz-Torné, C; Perez-Ruiz, F	1
Becker, MA; Gunawardhana, L; Hunt, B; MacDonald, P; Saag, KG; Whelton, A	1
Han, B; Xue, L; Yang, C	1
Chinchilla, SP; Perez-Ruiz, F; Urionaguena, I	1
Füeßl, HS; Stiefelhagen, P	1
Bäurle, A	1
Borghi, C; Perez-Ruiz, F	1
Fujimaki, K; Fujisaki, T; Gemba, K; Goto, T; Kaneko, M; Kawai, Y; Kiguchi, T; Kirito, K; Maemondo, M; Nakajima, A; Okamoto, M; Takeda, K; Tamura, K; Ueda, T	1
Mitri, G; Schulman, KL; Tidwell, BA; Turpin, RS; Wittbrodt, ET	1
Bakinde, N; Mome, R	1
Filiopoulos, V; Hadjiyannakos, D; Vlassopoulos, D	1
Sircar, D	1
Andrés, M; Gil, S; Pascual, E; Quilis, N; Ranieri, L; Vela, P	1
Christensen, HD; Hansen, IM; Morillon, MB; Sheta, HM	1
Hildebrand, BA; Jaster, P; Westgate, J	1
Day, RO; Graham, GG; Kamel, B; Kannangara, DR; Williams, KM	1
Carroll, MB; Shaak, TL; Smith, DM	1
Bailly, F; Bardin, T; Chalès, G; Cornec, D; Cornec-Le Gall, E; Dieudé, P; Ea, HK; Flipo, RM; Juge, PA; Lioté, F; Loustau, C; Ottaviani, S; Pascart, T; Pillebout, E; Richette, P; Saraux, A; Schaeverbeke, T; Snanoudj, R; Truchetet, ME; Vigneau, C	1
Li, Y; Lu, Y; Meng, J; Yuan, X	1
Bryant, CL; Fourakre, TN; Hughes, JC; Salvig, BE; Stone, WJ; Wallace, JL	1
Chen, X; Su, J; Tian, J; Zhou, Q; Zhou, T; Zhu, J	1
Aviña-Zubieta, JA; Choi, HK; De Vera, MA; McCormick, N; Rai, SK; Sayre, EC; Shojania, K	1
Lee, CT; Pei, SN; Poh, XE	1
Corbett, EJM; McGill, NW; Pentony, P	1
Abeles, AM	2
Becker, MA; Hunt, BJ; Joseph-Ridge, N; Lademacher, C; MacDonald, PA	1
Chen, LX; Schumacher, HR	1
Hair, PI; Keating, GM; McCormack, PL	1
Schlesinger, N	2
Edwards, NL	2
Sundy, JS	2
Becker, MA; Hunt, B; Joseph-Ridge, N; Lademacher, C; Macdonald, PA; Schumacher, HR; Streit, J; Wortmann, RL	1
Yu, KH	1
Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR	2
Traynor, K	1
Becker, MA; Chohan, S	1
Keenan, RT; Pillinger, MH	1
Lioté, F; Perez-Ruiz, F; Scavulli, J; Terkeltaub, R; Zelman, D	1
Pandor, A; Stevenson, M	2
Ernst, ME; Fravel, MA	1
Belavic, JM	1
Jansen, TL; Reinders, MK	1
Becker, MA; Espinoza, LR; Lademacher, C; Lloyd, E; MacDonald, P; Schumacher, HR; Wells, AF	1
Bardin, T; Barskova, V; Doherty, M; Guerne, PA; Jansen, TL; Leeb, B; Pascual, E; Perez-Ruiz, F; Pimentão, J; Punzi, L; Richette, P; Tausche, AK; Uhlig, T; Zimmermann-Górska, I	1
Barrons, R; Love, BL; Snider, KM; Veverka, A	1
Julkunen, H; Konttinen, YT	1
Burns, CM; Wortmann, RL	1
Quillen, DM	1
Graser, E; Pope, RS; Zychowicz, ME	1
El-Zawawy, H; Mandell, BF	1
Gunawardhana, L; Hunt, B; Macdonald, PA; Whelton, A; Zhao, L	1
Stiefelhagen, P	1
Cohen, MG	1
Gray, CL; Walters-Smith, NE	1
Hunt, B; Jackson, RL; Macdonald, PA; Wortmann, RL	1
Dubost, JJ; Mathieu, S; Soubrier, M	1
Doghramji, PP	1
Goldfarb, DS; Gunawardhana, L; Hunt, B; MacDonald, PA	1
El-Armouche, A; Emons, J; Wittköpper, K	1
Reid, G; Uh, M	1
Hosoya, T; Kamatani, N; Naoyuki, K; Tatsuo, H	1
Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H	2
Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M	3
Bardin, T; Ottaviani, S; Richette, P	1
Chohan, S	1
Al-Geizawi, S; Doares, W; Farney, A; Kaczmorski, S; Rogers, J; Stratta, R; Winfrey, S	1
Kriegsmann, J; Lange, U; Müller-Ladner, U; Panzner, I; Tausche, AK	1
Adenwalla, HN; O'Connor, CR	1
Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA	1
Schmidt, BM; Wagner, AD	1
Becker, MA; Gunawardhana, L; Hunt, B; MacDonald, PA	1
Das, P; Suresh, E	1
Chefo, S; Jackson, RL; MacDonald, PA; Wells, AF	1
Jutkowitz, E; Meltzer, M; Pizzi, LT	1
Hunt, B; Jackson, RL; MacDonald, PA	1
Duh, PD; Warnez, PM	1
Asmahan, MI; Hilmi, BA; Rosman, A	1
Richette, P	1
André, B; Bouquegneau, A; Delanaye, P; Dubois, BE	1
Chohan, S; Dabholkar, A; Hunt, B; Jackson, R; White, WB	1
Doghramji, PP; Mandell, BF; Pope, RS	1
Carey, JJ; Conway, R; Coughlan, RJ	1
Butani, L; Calogiuri, G; Di Leo, E; Ferrannini, A; Foti, C; Nettis, E	1
Herrero-Beites, AM; Perez-Ruiz, F	1
Keenan, RT	1
Lopez-Olivo, MA; Suarez-Almazor, ME; Tayar, JH	1
Chen, S; Cheng, Q; Li, Q; Liu, L; Luo, T; Lv, Q; Mei, M; Yang, S; Ye, P; Zhang, W	1
Chefo, S; Gunawardhana, L; MacDonald, PA; Whelton, A	1
Bomalaski, JS; Clark, MA	1
Hoshide, S; Kamatani, N; Kobayashi, H; Komoriya, K; Kubo, J; Nakachi, T; Takeda, K; Tsuchimoto, M; Yamanaka, H	1
Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Vernillet, L; Wortmann, RL	1
Schumacher, HR	1
Choy, G	1
Tomlinson, B	1
Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Streit, J; Wortmann, RL	1
Moreland, LW	1
Lustberg, ME	1
Gelber, AC	1
Ziegler, R	1
Bruce, SP	1
Hershfield, MS; Sundy, JS	1
Abeles, AM; Pillinger, MH; Rosenthal, P	1
Okamoto, K	1
Higashino, K; Hiroishi, K; Moriwaki, Y; Nasako, Y; Takahashi, S; Yamakita, J; Yamamoto, T	1
Couch, RC; Griffin, TB; Hasegawa, M; Horiuchi, H; Komoriya, K; Kondo, S; Osada, Y	1

Reviews

93 review(s) available for febuxostat and Gout

Article	Year
The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis. Annals of palliative medicine, 2021, Volume: 10, Issue:10 Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid	2021
Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. International journal of clinical pharmacology and therapeutics, 2022, Volume: 60, Issue:3 Topics: Benzbromarone; Benzothiazoles; Febuxostat; Gout; Gout Suppressants; Humans; Network Meta-Analysis; Randomized Controlled Trials as Topic; Treatment Outcome; Uric Acid; Uricosuric Agents	2022
Update on gout management: what is old and what is new. Current opinion in rheumatology, 2022, 03-01, Volume: 34, Issue:2 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Symptom Flare Up	2022
What's new on the front-line of gout pharmacotherapy? Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:4 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Quality of Life; Uric Acid	2022
Association between use of febuxostat and muscle injury: A disproportionality analysis and meta-analysis of randomized controlled trials. British journal of clinical pharmacology, 2023, Volume: 89, Issue:3 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Muscles; Muscular Diseases; Randomized Controlled Trials as Topic; Rhabdomyolysis	2023
Management of complex gout in clinical practice: Update on therapeutic approaches. Best practice & research. Clinical rheumatology, 2018, Volume: 32, Issue:6 Topics: Febuxostat; Gout; Gout Suppressants; Humans	2018
Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia. Clinical and experimental nephrology, 2020, Volume: 24, Issue:Suppl 1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Benzothiazoles; Drug Interactions; Febuxostat; Female; Gout; Humans; Hyperuricemia; Male; Uric Acid; Uricosuric Agents	2020
Debates in gout management. Current opinion in rheumatology, 2020, Volume: 32, Issue:2 Topics: Allopurinol; Disease Management; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Quality of Life	2020
Successful Desensitization to Febuxostat in a Patient With Hypersensitivity to Allopurinol and Febuxostat and Review of the Literature. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2021, Dec-01, Volume: 27, Issue:8S Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome	2021
Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials. Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:4 Topics: Allopurinol; Bayes Theorem; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Randomized Controlled Trials as Topic; Uric Acid	2020
Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review. Clinical rheumatology, 2020, Volume: 39, Issue:11 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome; Uric Acid	2020
Changing paradigms in the management of gout. The journal of the Royal College of Physicians of Edinburgh, 2020, Volume: 50, Issue:2 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Uric Acid	2020
Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials. Clinical rheumatology, 2021, Volume: 40, Issue:2 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid	2021
Febuxostat Use and Risks of Cardiovascular Disease Events, Cardiac Death, and All-cause Mortality: Metaanalysis of Randomized Controlled Trials. The Journal of rheumatology, 2021, Volume: 48, Issue:7 Topics: Cardiovascular Diseases; Death; Febuxostat; Gout; Humans; Randomized Controlled Trials as Topic	2021
Gout: Rapid Evidence Review. American family physician, 2020, 11-01, Volume: 102, Issue:9 Topics: Adrenal Cortex Hormones; Allopurinol; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Obesity; Risk Factors; Sex Factors; Uric Acid	2020
Efficacy and safety of Febuxostat Versus Allopurinol in Hyperuricemic patients with or without Gout: A meta-analysis. Neuro endocrinology letters, 2020, Volume: 41, Issue:4 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome	2020
Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021, Volume: 21, Issue:5 Topics: Cardiovascular Diseases; Colchicine; COVID-19; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Pandemics	2021
Medications for gout and its comorbidities: mutual benefits? Current opinion in rheumatology, 2021, 03-01, Volume: 33, Issue:2 Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Observational Studies as Topic; Symptom Flare Up	2021
The Management of Gout in Renal Disease. Seminars in nephrology, 2020, Volume: 40, Issue:6 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia	2020
Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. Expert opinion on pharmacotherapy, 2021, Volume: 22, Issue:11 Topics: Benzothiazoles; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid; Uricosuric Agents	2021
Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis. Clinical cardiology, 2021, Volume: 44, Issue:7 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Myocardial Infarction	2021
Interventions for tophi in gout. The Cochrane database of systematic reviews, 2021, 08-11, Volume: 8 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Randomized Controlled Trials as Topic; Thioglycolates; Triazoles; Urate Oxidase	2021
Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. Rheumatology (Oxford, England), 2017, 07-01, Volume: 56, Issue:7 Topics: Adult; Allopurinol; Arthritis, Gouty; Cardiovascular Diseases; Chronic Disease; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Polyethylene Glycols; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome; Urate Oxidase	2017
Lesinurad: A Review in Hyperuricaemia of Gout. Drugs & aging, 2017, Volume: 34, Issue:5 Topics: Adult; Allopurinol; Drug Therapy, Combination; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Kidney; Middle Aged; Organic Anion Transporters; Organic Cation Transport Proteins; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase	2017
Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol. European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:18 Topics: Adult; Allopurinol; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome; Uric Acid	2017
Gout: state of the art after a decade of developments. Rheumatology (Oxford, England), 2019, 01-01, Volume: 58, Issue:1 Topics: Allopurinol; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid; Xanthine Oxidase	2019
[Cardiovascular risk in gout patients : Cardiovascular Safety of Febuxostat or Allopurinol in Participants with Gout and Cardiovascular Comorbidities (CARES)]. Der Internist, 2018, Volume: 59, Issue:11 Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Risk Factors	2018
International position paper on the appropriate use of uricosurics with the introduction of lesinurad. Clinical rheumatology, 2018, Volume: 37, Issue:12 Topics: Benzbromarone; Europe; Febuxostat; Gout; Humans; International Cooperation; Practice Guidelines as Topic; Probenecid; Rheumatology; Thioglycolates; Triazoles; Uricosuric Agents; Xanthine Oxidase	2018
Gout - An update of aetiology, genetics, co-morbidities and management. Maturitas, 2018, Volume: 118 Topics: Allopurinol; Chronic Disease; Comorbidity; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thioglycolates; Triazoles; Uric Acid	2018
The Challenges of Approaching and Managing Gout. Rheumatic diseases clinics of North America, 2019, Volume: 45, Issue:1 Topics: Acetamides; Allopurinol; Antibodies, Monoclonal, Humanized; Colchicine; Diet Therapy; Febuxostat; Gout; Gout Suppressants; Humans; Medication Adherence; Patient Education as Topic; Phenylacetates; Polyethylene Glycols; Quality of Health Care; Rheumatology; Thioglycolates; Triazoles; Urate Oxidase; Uric Acid	2019
The role of febuxostat in gout. Current opinion in rheumatology, 2019, Volume: 31, Issue:2 Topics: Biomarkers; Febuxostat; Gout; Gout Suppressants; Humans; Uric Acid	2019
Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population-Based Cohort Study and Meta-Analysis. Clinical pharmacology and therapeutics, 2019, Volume: 106, Issue:2 Topics: Aged; Allopurinol; Asian People; Cardiovascular Diseases; Cohort Studies; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Febuxostat; Gout; Gout Suppressants; Humans; Middle Aged; Taiwan	2019
Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy. Drugs, 2019, Volume: 79, Issue:5 Topics: Allopurinol; Anti-Inflammatory Agents; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid	2019
Painless gouty tophus in the nasal bridge: A case report and literature review. Medicine, 2019, Volume: 98, Issue:11 Topics: Aged; Arthritis, Gouty; Biopsy, Fine-Needle; C-Reactive Protein; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Male; Nose; Prevalence; Tomography, X-Ray Computed; Uric Acid	2019
Cardiovascular Safety of Urate Lowering Therapies. Current rheumatology reports, 2019, 07-24, Volume: 21, Issue:9 Topics: Allopurinol; Cardiovascular Diseases; Endothelium; Febuxostat; Gout; Gout Suppressants; Heart Failure; Humans; Hypertension; Hyperuricemia; Myocardial Infarction; Probenecid; Risk; Stroke; Uricosuric Agents; Xanthine Oxidase	2019
The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2019, Volume: 29, Issue:10 Topics: Aged; Allopurinol; Asymptomatic Diseases; Biomarkers; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase	2019
A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Seminars in arthritis and rheumatism, 2013, Volume: 43, Issue:3 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcome; Uric Acid	2013
Safety profile of anti-gout agents: an update. Current opinion in rheumatology, 2014, Volume: 26, Issue:2 Topics: Allopurinol; Colchicine; Drug Interactions; Febuxostat; Gout; Gout Suppressants; HLA-B Antigens; Humans; Interleukin-1; Polyethylene Glycols; Risk Factors; Safety; Thiazoles; Urate Oxidase	2014
Therapeutic approaches to chronic hyperuricemia and gout. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2014, Volume: 21, Issue:4 Topics: Allopurinol; Cardiovascular Diseases; Chronic Disease; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Life Style; Patient Education as Topic; Thiazoles; Xanthine Oxidase	2014
Long-term management of gout: nonpharmacologic and pharmacologic therapies. Rheumatic diseases clinics of North America, 2014, Volume: 40, Issue:2 Topics: Allopurinol; Benzbromarone; Chronic Disease; Febuxostat; Feeding Behavior; Gout; Gout Suppressants; Humans; Hyperuricemia; Polyethylene Glycols; Risk Reduction Behavior; Thiazoles; Urate Oxidase; Uricosuric Agents	2014
Emerging therapies for gout. Rheumatic diseases clinics of North America, 2014, Volume: 40, Issue:2 Topics: Acetamides; Adrenocorticotropic Hormone; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Benzodiazepines; Febuxostat; Gout; Gout Suppressants; Humans; Imino Furanoses; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Melanocortins; Phenylacetates; Polyethylene Glycols; Pyrimidinones; Recombinant Fusion Proteins; Thiazoles; Thioglycolates; Triazoles; Urate Oxidase; Uricosuric Agents	2014
Clinical inquiry: Which prophylactic therapies best prevent gout attacks? The Journal of family practice, 2014, Volume: 63, Issue:4 Topics: Allopurinol; Colchicine; Evidence-Based Medicine; Febuxostat; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Quality of Life; Thiazoles; Urate Oxidase	2014
Allopurinol for chronic gout. The Cochrane database of systematic reviews, 2014, Oct-14, Issue:10 Topics: Allopurinol; Benzbromarone; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Probenecid; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid	2014
Advances in pharmacotherapy for the treatment of gout. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:4 Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzbromarone; Clinical Trials, Phase III as Topic; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Probenecid; Thiazoles; Urate Oxidase; Uric Acid	2015
Febuxostat for the treatment of gout. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:3 Topics: Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Xanthine Oxidase	2015
Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout. Drugs, 2015, Volume: 75, Issue:4 Topics: Clinical Trials, Phase III as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome	2015
[A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient]. Yao xue xue bao = Acta pharmaceutica Sinica, 2014, Volume: 49, Issue:12 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Uric Acid	2014
[Hyperuricemia. When and how to treat?]. Der Internist, 2016, Volume: 57, Issue:2 Topics: Allopurinol; Evidence-Based Medicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Internationality; Practice Guidelines as Topic; Treatment Outcome; Uricosuric Agents	2016
Febuxostat for the chronic management of hyperuricemia in patients with gout. Expert review of clinical pharmacology, 2016, Volume: 9, Issue:5 Topics: Drug Administration Schedule; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia	2016
Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis. European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:5 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid	2016
Xanthine oxidoreductase and its inhibitors: relevance for gout. Clinical science (London, England : 1979), 2016, 12-01, Volume: 130, Issue:23 Topics: Allopurinol; Animals; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hypoxanthine; Uric Acid; Xanthine Dehydrogenase	2016
Major unanswered questions in the clinical gout field. Current opinion in rheumatology, 2017, Volume: 29, Issue:2 Topics: Allopurinol; Benzbromarone; Colchicine; Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Patient Care Planning; Probenecid; Renal Insufficiency, Chronic; Uric Acid; Uricosuric Agents	2017
Febuxostat. Drugs, 2008, Volume: 68, Issue:13 Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Molecular Structure; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Uric Acid	2008
Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Recent patents on inflammation & allergy drug discovery, 2007, Volume: 1, Issue:1 Topics: Animals; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Patents as Topic; Thiazoles; Xanthine Oxidase	2007
Update on emerging urate-lowering therapies. Current opinion in rheumatology, 2009, Volume: 21, Issue:2 Topics: Allopurinol; Drug Discovery; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Thiazoles; United States; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase	2009
Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology (Oxford, England), 2009, Volume: 48 Suppl 2 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles	2009
Febuxostat (Uloric) for chronic treatment of gout. The Medical letter on drugs and therapeutics, 2009, May-18, Volume: 51, Issue:1312 Topics: Chronic Disease; Clinical Trials as Topic; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles	2009
Febuxostat: a new agent for lowering serum urate. Drugs of today (Barcelona, Spain : 1998), 2009, Volume: 45, Issue:4 Topics: Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Liver Diseases; Thiazoles	2009
Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal. Health technology assessment (Winchester, England), 2009, Volume: 13 Suppl 3 Topics: Allopurinol; Cost-Benefit Analysis; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles	2009
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clinical therapeutics, 2009, Volume: 31, Issue:11 Topics: Allopurinol; Biotransformation; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Half-Life; Humans; Hyperuricemia; Thiazoles; Tissue Distribution; Uric Acid; Xanthine Dehydrogenase; Xanthine Oxidase	2009
Progress in the pharmacotherapy of gout. Current opinion in rheumatology, 2010, Volume: 22, Issue:2 Topics: Allopurinol; Clinical Trials as Topic; Colchicine; Drug Therapy, Combination; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Recombinant Fusion Proteins; Thiazoles; Uricosuric Agents	2010
Management of hyperuricemia in gout: focus on febuxostat. Clinical interventions in aging, 2010, Feb-02, Volume: 5 Topics: Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcome; Xanthine Oxidase	2010
International position paper on febuxostat. Clinical rheumatology, 2010, Volume: 29, Issue:8 Topics: Febuxostat; Gout; Gout Suppressants; Humans; International Cooperation; Thiazoles; Treatment Outcome; Xanthine Oxidase	2010
New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond. Current rheumatology reports, 2010, Volume: 12, Issue:2 Topics: Acute Disease; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Polyethylene Glycols; Thiazoles; Urate Oxidase	2010
Urate-lowering therapy for gout: focus on febuxostat. Pharmacotherapy, 2010, Volume: 30, Issue:6 Topics: Clinical Trials as Topic; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Models, Biological; Thiazoles; Xanthine Oxidase	2010
[The clinical picture of gout is changing]. Duodecim; laaketieteellinen aikakauskirja, 2010, Volume: 126, Issue:12 Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Probenecid; Risk Factors; Thiazoles; Uricosuric Agents	2010
Gout therapeutics: new drugs for an old disease. Lancet (London, England), 2011, Jan-08, Volume: 377, Issue:9760 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Drug Administration Schedule; Drug Approval; Enzyme Inhibitors; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Thiazoles; United States; United States Food and Drug Administration; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase	2011
Advances in gout: some answers, more questions. Arthritis research & therapy, 2010, Volume: 12, Issue:5 Topics: Allopurinol; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles	2010
Crystal arthropathies: recognizing and treating "the gouch". Primary care, 2010, Volume: 37, Issue:4 Topics: Allopurinol; Antimetabolites; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thiazoles; Uric Acid; Uricosuric Agents	2010
Managing gout: how is it different in patients with chronic kidney disease? Cleveland Clinic journal of medicine, 2010, Volume: 77, Issue:12 Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Comorbidity; Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Kidney Failure, Chronic; Risk Factors; Thiazoles	2010
Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. PharmacoEconomics, 2011, Volume: 29, Issue:2 Topics: Biomedical Technology; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles	2011
Febuxostat for treatment of chronic gout. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2011, Mar-01, Volume: 68, Issue:5 Topics: Allopurinol; Animals; Chronic Disease; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Xanthine Oxidase	2011
[Treatment of gout]. La Revue de medecine interne, 2011, Volume: 32, Issue:12 Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid; Uricosuric Agents	2011
Managing your patient with gout: a review of treatment options. Postgraduate medicine, 2011, Volume: 123, Issue:3 Topics: Allopurinol; Anti-Inflammatory Agents; Colchicine; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Life Style; Patient Education as Topic; Quality of Life; Risk Factors; Thiazoles	2011
[Febuxostat]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:23 Topics: Allopurinol; Enzyme Activation; Febuxostat; Gout; Gout Suppressants; Humans; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid; Xanthine Oxidase	2011
A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:4 Suppl 2 Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Primary Health Care; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase	2011
[New therapeutic options for gout]. Presse medicale (Paris, France : 1983), 2011, Volume: 40, Issue:9 Pt 1 Topics: Allopurinol; Controlled Clinical Trials as Topic; Drug Approval; Drugs, Investigational; Febuxostat; Gout; Gout Suppressants; Humans; Interleukin-1beta; Organic Anion Transporters; Polyethylene Glycols; Recombinant Proteins; Thiazoles; Urate Oxidase	2011
[Gout - regardless of therapeutic options a "forgotten" disease]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:33 Topics: Allopurinol; Arthritis, Gouty; Benzbromarone; Combined Modality Therapy; Cytokines; Europe; Febuxostat; Gout; Gout Suppressants; Guideline Adherence; Humans; Inflammasomes; Interleukin-1; Long-Term Care; Probenecid; Signal Transduction; Thiazoles; Uric Acid	2011
[Hyperuricemia, gout, pseudogout and concomitant diseases]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:48 Topics: Allopurinol; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Chondrocalcinosis; Comorbidity; Diabetes Mellitus, Type 2; Febuxostat; Gout; Gout Suppressants; Guideline Adherence; Humans; Hypertrophy, Left Ventricular; Hyperuricemia; Interleukin 1 Receptor Antagonist Protein; Kidney Failure, Chronic; Thiazoles; Xanthine Oxidase	2011
Recent advances in management of gout. QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:5 Topics: Adrenal Cortex Hormones; Alcohol Drinking; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Ascorbic Acid; Colchicine; Comorbidity; Cryotherapy; Diet; Dose-Response Relationship, Drug; Febuxostat; Fructose; Gout; Gout Suppressants; Humans; Interleukin 1 Receptor Antagonist Protein; Polyethylene Glycols; Purines; Receptors, Interleukin-1; Recombinant Fusion Proteins; Thiazoles; Urate Oxidase; Uric Acid; Uricosuric Agents; Vitamins; Xanthine Oxidase	2012
[Pharmacological sheet. Febuxostat, oral (Adenuric)]. Journal de pharmacie de Belgique, 2012, Issue:1 Topics: Contraindications; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles	2012
[Gout: an overview of available urate lowering therapies]. Annales pharmaceutiques francaises, 2012, Volume: 70, Issue:3 Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Guidelines as Topic; Humans; Organ Transplantation; Polyethylene Glycols; Thiazoles; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase	2012
Evaluation and treatment of gout as a chronic disease. Advances in therapy, 2012, Volume: 29, Issue:11 Topics: Arthritis, Gouty; Chronic Disease; Disease Progression; Evaluation Studies as Topic; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Male; Pain Measurement; Polyethylene Glycols; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Thiazoles; Treatment Outcome; Urate Oxidase; Uric Acid	2012
Safety of urate-lowering therapies: managing the risks to gain the benefits. Rheumatic diseases clinics of North America, 2012, Volume: 38, Issue:4 Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; Thiazoles; Uric Acid	2012
Febuxostat for treating chronic gout. The Cochrane database of systematic reviews, 2012, Nov-14, Volume: 11 Topics: Allopurinol; Chronic Disease; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Randomized Controlled Trials as Topic; Thiazoles	2012
Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. Clinical therapeutics, 2013, Volume: 35, Issue:2 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid	2013
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Current rheumatology reports, 2004, Volume: 6, Issue:3 Topics: Allopurinol; Amlodipine; Clinical Trials as Topic; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Losartan; Pyrazoles; Thiazoles; Treatment Outcome; Urate Oxidase; Uric Acid; Xanthine Oxidase	2004
Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert opinion on investigational drugs, 2005, Volume: 14, Issue:7 Topics: Disease Management; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Thiazoles; Xanthine Oxidase	2005
An update on the treatment options for gout and calcium pyrophosphate deposition. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:14 Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Allopurinol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Chondrocalcinosis; Colchicine; Drug Combinations; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Multicenter Studies as Topic; Probenecid; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase	2005
Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. The Annals of pharmacotherapy, 2006, Volume: 40, Issue:12 Topics: Febuxostat; Gout; Humans; Hyperuricemia; Thiazoles; Xanthine Oxidase	2006
Uricase and other novel agents for the management of patients with treatment-failure gout. Current rheumatology reports, 2007, Volume: 9, Issue:3 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiazoles; Treatment Failure; Urate Oxidase; Uric Acid	2007
Hyperuricemia and gout: new insights into pathogenesis and treatment. Bulletin of the NYU hospital for joint diseases, 2007, Volume: 65, Issue:3 Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Interleukin 1 Receptor Antagonist Protein; Thiazoles; Urate Oxidase; Uric Acid	2007
[Inhibitors of xanthine oxidoreductase]. Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:4 Topics: Allopurinol; Drug Design; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Nitriles; Pyrazoles; Pyridines; Thiazoles; Xanthine Dehydrogenase	2008

Trials

60 trial(s) available for febuxostat and Gout

Article	Year
Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial. Rheumatology (Oxford, England), 2022, 05-30, Volume: 61, Issue:6 Topics: Aged; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid	2022
Effect of alkalized urine on renal calculi in patients with gout: a protocol for a placebo-controlled, double-blinded randomized controlled trial. Trials, 2021, Oct-26, Volume: 22, Issue:1 Topics: Double-Blind Method; Febuxostat; Gout; Gout Suppressants; Humans; Kidney Calculi; Randomized Controlled Trials as Topic; Treatment Outcome; Uric Acid	2021
Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease. International journal of cardiology, 2022, Feb-15, Volume: 349 Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome	2022
Intensive Serum Urate Lowering With Oral Urate-Lowering Therapy for Erosive Gout: A Randomized Double-Blind Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.), 2022, Volume: 74, Issue:6 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Quality of Life; Treatment Outcome; Uric Acid	2022
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. Arthritis & rheumatology (Hoboken, N.J.), 2022, Volume: 74, Issue:9 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcome; Uric Acid	2022
Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion. Arthritis & rheumatology (Hoboken, N.J.), 2022, Volume: 74, Issue:12 Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Prospective Studies; Treatment Outcome; Uric Acid	2022
A Drug-Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia. Journal of clinical pharmacology, 2023, Volume: 63, Issue:2 Topics: Drug Interactions; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid; Xanthine Oxidase	2023
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study. Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:12 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid	2022
Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial. Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:7 Topics: Double-Blind Method; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Symptom Flare Up; Treatment Outcome; Uric Acid	2023
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial. Hypertension research : official journal of the Japanese Society of Hypertension, 2023, Volume: 46, Issue:6 Topics: Aged; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid	2023
Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort. Arthritis research & therapy, 2019, 09-02, Volume: 21, Issue:1 Topics: Benzbromarone; Biomarkers; China; Dose-Response Relationship, Drug; Febuxostat; Follow-Up Studies; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Kidney; Male; Middle Aged; Prospective Studies; Treatment Outcome; Uric Acid; Uricosuric Agents	2019
Class effect of xanthine oxidase inhibitors on flow-mediated dilatation in hypertensive patients: A randomized controlled trial. Journal of clinical hypertension (Greenwich, Conn.), 2020, Volume: 22, Issue:3 Topics: Aged; Allopurinol; Dilatation; Febuxostat; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Treatment Outcome; Xanthine Oxidase	2020
A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout. Clinical and experimental nephrology, 2020, Volume: 24, Issue:Suppl 1 Topics: Adult; Aged; Benzothiazoles; Double-Blind Method; Febuxostat; Gout; Humans; Hyperuricemia; Japan; Male; Middle Aged; Treatment Outcome; Uric Acid; Uricosuric Agents	2020
Evaluation of febuxostat initiation during an acute gout attack: A prospective, randomized clinical trial. Joint bone spine, 2020, Volume: 87, Issue:5 Topics: Febuxostat; Gout; Gout Suppressants; Humans; Neoplasm Recurrence, Local; Prospective Studies; Symptom Flare Up; Treatment Outcome	2020
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet (London, England), 2020, 11-28, Volume: 396, Issue:10264 Topics: Aged; Allopurinol; Cardiovascular Diseases; Denmark; Febuxostat; Female; Gout; Gout Suppressants; Hospitalization; Humans; Male; Prospective Studies; Sweden; Treatment Outcome; United Kingdom; Uric Acid	2020
Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial. Rheumatology (Oxford, England), 2021, 09-01, Volume: 60, Issue:9 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Single-Blind Method; Symptom Flare Up; Treatment Outcome; Uric Acid	2021
Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study. European heart journal. Cardiovascular pharmacotherapy, 2022, 05-05, Volume: 8, Issue:3 Topics: Adult; Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Pulse Wave Analysis; Risk Factors; Thiazoles; Treatment Outcome; Uric Acid	2022
Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:9 Topics: Creatinine; Double-Blind Method; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid	2017
Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study. Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:12 Topics: Adult; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Joints; Magnetic Resonance Imaging; Male; Middle Aged; Synovitis; Treatment Outcome; Uric Acid	2017
Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Annals of the rheumatic diseases, 2018, Volume: 77, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans; Incidence; Male; Middle Aged; Prospective Studies; Symptom Flare Up; Uric Acid	2018
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. The New England journal of medicine, 2018, Mar-29, Volume: 378, Issue:13 Topics: Aged; Allopurinol; Cardiovascular Diseases; Cause of Death; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged	2018
Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial. Contemporary clinical trials, 2018, Volume: 68 Topics: Adult; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Dosage Calculations; Drug Monitoring; Febuxostat; Gout; Gout Suppressants; Humans; Male; Medication Therapy Management; Middle Aged; Practice Guidelines as Topic; Treatment Outcome; United States; United States Department of Veterans Affairs; Uric Acid; Veterans Health	2018
Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis research & therapy, 2018, 05-30, Volume: 20, Issue:1 Topics: Aged; Cardiovascular Diseases; Delayed-Action Preparations; Double-Blind Method; Febuxostat; Female; Gastrointestinal Diseases; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Kidney Diseases; Male; Middle Aged; Treatment Outcome	2018
Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. Rheumatology (Oxford, England), 2018, 09-01, Volume: 57, Issue:9 Topics: Administration, Oral; Adult; Aged; Benzbromarone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Organic Anion Transporters; Organic Cation Transport Proteins; Thioglycolates; Time Factors; Treatment Outcome; Triazoles; Uric Acid; Uricosuric Agents; Young Adult	2018
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:1 Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Colchicine; Cough; Creatinine; Delayed-Action Preparations; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Febuxostat; Female; gamma-Glutamyltransferase; Glomerular Filtration Rate; Gout; Gout Suppressants; Headache; Humans; Hypertension; Male; Middle Aged; Naproxen; Nasopharyngitis; Renal Insufficiency, Chronic; Respiratory Tract Infections; Severity of Illness Index; Treatment Outcome; Uric Acid	2019
The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia. Pakistan journal of pharmaceutical sciences, 2018, Volume: 31, Issue:4(Special) Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Treatment Outcome; Uric Acid	2018
Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis research & therapy, 2019, 01-07, Volume: 21, Issue:1 Topics: Adult; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Thioglycolates; Treatment Outcome; Triazoles; Uricosuric Agents	2019
Does the provision of a DVD-based audio-visual presentation improve recruitment in a clinical trial? A randomised trial of DVD trial invitations. BMC medical research methodology, 2019, 01-30, Volume: 19, Issue:1 Topics: Aged; Allopurinol; Audiovisual Aids; Febuxostat; Female; Gout; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Patient Education as Topic; Patient Selection	2019
Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Body Mass Index; Cohort Studies; Comorbidity; Diabetes Complications; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Intention to Treat Analysis; Kidney; Lost to Follow-Up; Male; Middle Aged; Obesity; Patient Dropouts; Renal Insufficiency; Thiazoles; Xanthine Oxidase; Young Adult	2013
As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. Rheumatology international, 2014, Volume: 34, Issue:1 Topics: Aged; Allopurinol; Biomarkers; Chronic Disease; Enzyme Inhibitors; Febuxostat; Germany; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Inflammation Mediators; Kidney; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pulse Wave Analysis; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Vascular Stiffness; Xanthine Oxidase	2014
An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. International journal of rheumatic diseases, 2014, Volume: 17, Issue:6 Topics: Adult; Allopurinol; Biomarkers; China; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Remission Induction; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase	2014
Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology (Oxford, England), 2014, Volume: 53, Issue:12 Topics: Adult; Aged; Colchicine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Thioglycolates; Triazoles; Uric Acid	2014
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ open, 2014, Jul-10, Volume: 4, Issue:7 Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Prospective Studies; Research Design	2014
Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men. Journal of Korean medical science, 2014, Volume: 29, Issue:8 Topics: Allopurinol; Biomarkers; Blood Pressure; Creatinine; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans; Hypertension, Renal; Male; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Thiazoles; Treatment Outcome	2014
A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. International journal of rheumatic diseases, 2015, Volume: 18, Issue:6 Topics: Administration, Oral; Adult; Allopurinol; Biomarkers; China; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Time Factors; Treatment Outcome; Uric Acid	2015
Combination Therapies of Diacerein and Febuxostat Inhibit IL-1β Responses and Improve Clinical Symptoms in Patients With Refractory Gout. American journal of therapeutics, 2017, Volume: 24, Issue:3 Topics: Adult; Anthraquinones; Anti-Inflammatory Agents; C-Reactive Protein; Case-Control Studies; Drug Therapy, Combination; Etoricoxib; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Interleukin-18; Interleukin-1beta; Male; Middle Aged; Prospective Studies; Pyridines; Sulfones; Treatment Outcome; Uric Acid	2017
Safety and efficacy of oral febuxostat for treatment of HLA-B5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. Scandinavian journal of rheumatology, 2016, Volume: 45, Issue:4* Topics: Administration, Oral; Adult; Alleles; Allopurinol; China; Febuxostat; Female; Gout; Gout Suppressants; HLA-B Antigens; Humans; Hyperuricemia; Male; Middle Aged; Treatment Outcome; Uric Acid	2016
Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. Arthritis & rheumatology (Hoboken, N.J.), 2016, Volume: 68, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Febuxostat; Female; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Male; Middle Aged; Prospective Studies; Renal Insufficiency; Severity of Illness Index	2016
Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. International journal of clinical oncology, 2016, Volume: 21, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Neoplasms; Thiazoles; Tumor Lysis Syndrome; Uric Acid; Xanthine Oxidase; Young Adult	2016
Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides, nucleotides & nucleic acids, 2008, Volume: 27, Issue:6 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Linear Models; Multivariate Analysis; Odds Ratio; Thiazoles; Time Factors; Treatment Outcome	2008
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis and rheumatism, 2008, Nov-15, Volume: 59, Issue:11 Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid	2008
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford, England), 2009, Volume: 48, Issue:2 Topics: Adult; Aged; Biomarkers; Clinical Trials, Phase II as Topic; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Joints; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Young Adult	2009
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis research & therapy, 2010, Volume: 12, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Drug; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperlipidemias; Hypertension; Hyperuricemia; Kidney Diseases; Male; Middle Aged; Obesity; Thiazoles; Treatment Outcome; United States; Uric Acid; Young Adult	2010
Renal function in gout: long-term treatment effects of febuxostat. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:1 Topics: Adult; Aged; Double-Blind Method; Febuxostat; Female; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Thiazoles; Young Adult	2011
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clinical therapeutics, 2010, Volume: 32, Issue:14 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Schedule; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Young Adult	2010
Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. The Journal of rheumatology, 2011, Volume: 38, Issue:7 Topics: Adult; Aged; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase	2011
An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: p Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:4 Suppl 2 Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase	2011
Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:4 Suppl 2 Topics: Adult; Central Nervous System Diseases; Dental Enamel; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Japan; Kidney Diseases, Cystic; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase	2011
Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:4 Suppl 2 Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase	2011
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phas Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:4 Suppl 2 Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase	2011
Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:4 Suppl 2 Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase	2011
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis care & research, 2012, Volume: 64, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Illinois; Male; Metabolic Diseases; Middle Aged; Obesity; Retrospective Studies; Sex Factors; Thiazoles; Treatment Outcome; Uric Acid; Young Adult	2012
Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides, nucleotides & nucleic acids, 2011, Volume: 30, Issue:12 Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Liver Function Tests; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid	2011
African American patients with gout: efficacy and safety of febuxostat vs allopurinol. BMC musculoskeletal disorders, 2012, Feb-09, Volume: 13 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Black or African American; Comorbidity; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Thiazoles; White People; Young Adult	2012
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. BMC geriatrics, 2012, Mar-21, Volume: 12 Topics: Aged; Aged, 80 and over; Biomarkers; Cohort Studies; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase	2012
Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. American heart journal, 2012, Volume: 164, Issue:1 Topics: Allopurinol; Cardiovascular Diseases; Double-Blind Method; Febuxostat; Gout; Gout Suppressants; Humans; Prospective Studies; Thiazoles	2012
Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgraduate medicine, 2013, Volume: 125, Issue:1 Topics: Adult; Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney; Kidney Function Tests; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid	2013
Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides, nucleotides & nucleic acids, 2004, Volume: 23, Issue:8-9 Topics: Area Under Curve; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Male; Oxygen; Thiazoles; Time Factors; Xanthine Dehydrogenase; Xanthine Oxidase	2004
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis and rheumatism, 2005, Volume: 52, Issue:3 Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase	2005
Febuxostat compared with allopurinol in patients with hyperuricemia and gout. The New England journal of medicine, 2005, Dec-08, Volume: 353, Issue:23 Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Uric Acid; Xanthine Oxidase	2005

Other Studies

214 other study(ies) available for febuxostat and Gout

Article	Year
Cardiovascular safety of febuxostat. Lancet (London, England), 2021, 09-11, Volume: 398, Issue:10304 Topics: Febuxostat; Gout; Gout Suppressants; Humans	2021
Cardiovascular safety of febuxostat - Authors' reply. Lancet (London, England), 2021, 09-11, Volume: 398, Issue:10304 Topics: Febuxostat; Gout; Gout Suppressants; Humans	2021
Cardiovascular safety of febuxostat. Lancet (London, England), 2021, 09-11, Volume: 398, Issue:10304 Topics: Febuxostat; Gout; Gout Suppressants; Humans	2021
Incorporating gout guideline advice into urate reports is associated with reduced hospital admissions: results of an observational study. Rheumatology (Oxford, England), 2022, 05-05, Volume: 61, Issue:5 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Hospitals; Humans; Treatment Outcome; Uric Acid	2022
Clinical characteristics of juvenile gout and treatment response to febuxostat. Annals of the rheumatic diseases, 2022, Volume: 81, Issue:4 Topics: Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Male; Treatment Outcome	2022
Colchicine use and the risk of CKD progression: a multicentre nested case-control study. Rheumatology (Oxford, England), 2022, 11-02, Volume: 61, Issue:11 Topics: Case-Control Studies; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid	2022
Treating gout - can hypouricemia produced by moderate doses of combined oral treatment give early treatment success? Preliminary observations. Nucleosides, nucleotides & nucleic acids, 2022, Volume: 41, Issue:12 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Male; Treatment Outcome; Uric Acid	2022
Hypersensitivity to Febuxostat in a Patient with a Previous Allopurinolinduced Steven-Johnson Syndrome: A Case Report of Treatment with a Slow Desensitization Protocol. Endocrine, metabolic & immune disorders drug targets, 2022, Volume: 22, Issue:8 Topics: Adult; Febuxostat; Gout; Gout Suppressants; Humans; Hypersensitivity; Male; Thiazoles	2022
Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017. Rheumatology international, 2022, Volume: 42, Issue:9 Topics: Aged; Allopurinol; Austria; Cardiovascular Diseases; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Hyperuricemia; Ischemic Stroke; Male; Retrospective Studies; Risk Factors; Uric Acid	2022
Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis. Clinical cardiology, 2022, Volume: 45, Issue:7 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia	2022
Reply to comment on "Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis". Clinical cardiology, 2022, Volume: 45, Issue:7 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans	2022
Febuxostat Use and Safety in Patients With Hyperuricemia. The Journal of rheumatology, 2022, Volume: 49, Issue:10 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome	2022
Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. RMD open, 2022, Volume: 8, Issue:2 Topics: Allopurinol; Cardiovascular Diseases; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans	2022
Simulation of febuxostat pharmacokinetics in healthy subjects and patients with impaired kidney function using physiologically based pharmacokinetic modeling. Biopharmaceutics & drug disposition, 2022, Volume: 43, Issue:4 Topics: Febuxostat; Gout; Gout Suppressants; Healthy Volunteers; Humans; Kidney; Renal Insufficiency	2022
Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout. British journal of clinical pharmacology, 2022, Volume: 88, Issue:12 Topics: Biological Availability; Febuxostat; Gout; Healthy Volunteers; Humans; Models, Biological	2022
Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes. Arthritis research & therapy, 2022, 07-25, Volume: 24, Issue:1 Topics: Adipocytes; Allopurinol; Colchicine; Enzyme Inhibitors; Fatty Acids, Nonesterified; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Inflammation; Lipolysis; Prospective Studies; Uric Acid; Xanthine Oxidase	2022
Is febuxostat associated with higher risk of cardiovascular death than allopurinol in treating gout or asymptomatic hyperuricemia? Annals of palliative medicine, 2022, Volume: 11, Issue:8 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid	2022
Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat. Seminars in arthritis and rheumatism, 2022, Volume: 56 Topics: Allopurinol; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Myocardial Infarction; Treatment Outcome	2022
Praxis, 2022, Volume: 111, Issue:11 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans	2022
A new Febuxostat-Telmisartan Drug-Drug Cocrystal for Gout-Hypertension Combination Therapy. Journal of pharmaceutical sciences, 2022, Volume: 111, Issue:12 Topics: Combined Modality Therapy; Febuxostat; Gout; Humans; Hypertension; Sodium Chloride; Sodium Chloride, Dietary; Telmisartan	2022
Discovery of novel 1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors with hypouricemic effects. Bioorganic chemistry, 2022, Volume: 129 Topics: Animals; Enzyme Inhibitors; Febuxostat; Gout; Hyperuricemia; Mice; Triazoles; Xanthine Dehydrogenase; Xanthine Oxidase	2022
Febuxostat, a potential drug in the secondary prevention of cardiovascular disease with hyperuricemia. International journal of cardiology, 2023, 01-01, Volume: 370 Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Secondary Prevention; Treatment Outcome	2023
Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Clinical and translational science, 2023, Volume: 16, Issue:2 Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Insurance, Health; Japan; Risk Factors; Treatment Outcome; Uric Acid	2023
A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout. The Korean journal of internal medicine, 2023, Volume: 38, Issue:3 Topics: Adult; Aged; Allopurinol; Arthritis, Gouty; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Uric Acid	2023
`Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea. Rheumatology international, 2023, Volume: 43, Issue:2 Topics: Allopurinol; Cardiovascular Diseases; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Republic of Korea; Retrospective Studies	2023
Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study. Drugs, 2022, Volume: 82, Issue:18 Topics: Adult; Allopurinol; Cohort Studies; Erectile Dysfunction; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male	2022
Assessing tophaceous spinal gout treatment response using dual-energy CT as a point-of-care imaging modality: case report. Skeletal radiology, 2023, Volume: 52, Issue:8 Topics: Aged; Febuxostat; Gout; Humans; Male; Point-of-Care Systems; Tomography, X-Ray Computed; Uric Acid	2023
Effect of febuxostat on adverse events and mortality in gout in Taiwan: An interrupted time series analysis. International journal of rheumatic diseases, 2023, Volume: 26, Issue:3 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Interrupted Time Series Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Retrospective Studies; Taiwan	2023
Gout Prevalence, Practice Patterns, and Associations with Outcomes in North American Dialysis Patients. Kidney360, 2023, 01-01, Volume: 4, Issue:1 Topics: Allopurinol; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Male; Prevalence; Quality of Life; Renal Dialysis	2023
A lifetime economic research of universal HLA-B58:01 genotyping or febuxostat initiation therapy in Chinese gout patients with mild to moderate chronic kidney disease. Pharmacogenetics and genomics, 2023, 02-01, Volume: 33, Issue:2* Topics: Allopurinol; China; Cost-Benefit Analysis; East Asian People; Febuxostat; Gout; Gout Suppressants; HLA-B Antigens; Humans; Quality-Adjusted Life Years; Renal Insufficiency, Chronic	2023
Clinical observation of Febuxostat in the treatment of gout patients with different body fat levels. Minerva medica, 2023, Volume: 114, Issue:3 Topics: Adipose Tissue; Febuxostat; Gout; Humans; Hyperuricemia; Treatment Outcome	2023
Superiority of low-dose benzbromarone to low-dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al. Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:9 Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid	2023
Towards the Development of Dual Hypouricemic and Anti-inflammatory Candidates: Design, Synthesis, Stability Studies and Biological Evaluation of Some Mutual Ester Prodrugs of Febuxostat-NSAIDs. Bioorganic chemistry, 2023, Volume: 135 Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Esters; Febuxostat; Gout; Humans; Prodrugs; Uric Acid	2023
Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis. American journal of nephrology, 2023, Volume: 54, Issue:3-4 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Treatment Outcome; Uric Acid	2023
Safety update: febuxostat and CVD. Drug and therapeutics bulletin, 2023, Volume: 61, Issue:7 Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid	2023
Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database. International journal of rheumatic diseases, 2023, Volume: 26, Issue:9 Topics: Adult; Allopurinol; Colchicine; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Insurance Claim Review; Insurance, Health; Republic of Korea; Retrospective Studies; Uric Acid; Xanthine Oxidase; Young Adult	2023
Evaluation of Treatment Success Rate Among Antihyperuricemic Using Real-World Data. Studies in health technology and informatics, 2019, Aug-21, Volume: 264 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid	2019
Rising Incidence of Acute Hospital Admissions due to Gout. The Journal of rheumatology, 2020, Volume: 47, Issue:4 Topics: Adult; Allopurinol; Febuxostat; Gout; Gout Suppressants; Hospitals; Humans; Incidence; State Medicine	2020
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients. Arthritis research & therapy, 2019, 09-18, Volume: 21, Issue:1 Topics: Allopurinol; Benzbromarone; Disease Progression; Febuxostat; Female; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Incidence; Male; Middle Aged; Recovery of Function; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid; Uricosuric Agents	2019
Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study. Arthritis research & therapy, 2019, 11-08, Volume: 21, Issue:1 Topics: Acute Kidney Injury; Adult; Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Pharmacovigilance; Product Surveillance, Postmarketing; Treatment Outcome	2019
Discontinuing febuxostat might cause more deaths than continuing febuxostat: the untold story from the CARES trial. Rheumatology (Oxford, England), 2020, 06-01, Volume: 59, Issue:6 Topics: Adult; Allopurinol; Cardiovascular Diseases; Cause of Death; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome; Withholding Treatment	2020
Burden and management of gout in a multi-ethnic Asian cohort. Rheumatology international, 2020, Volume: 40, Issue:7 Topics: Adult; Aged; Allopurinol; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Dyslipidemias; Emergency Service, Hospital; Ethnicity; Febuxostat; Female; Gout; Gout Suppressants; Hospitalization; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Probenecid; Renal Insufficiency, Chronic; Severity of Illness Index; Singapore; Treatment Outcome; Uric Acid	2020
Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users. Rheumatology (Oxford, England), 2020, 09-01, Volume: 59, Issue:9 Topics: Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Male; Middle Aged; Retrospective Studies; Xanthine Oxidase	2020
Efficacy and tolerability of febuxostat in gout patients on dialysis. Internal medicine journal, 2021, Volume: 51, Issue:3 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Retrospective Studies; Treatment Outcome; Uric Acid	2021
A Rare Presentation of Gout: Achilles Tendinopathy, Ultrasonographic Assessment. The American journal of the medical sciences, 2020, Volume: 359, Issue:4 Topics: Achilles Tendon; Febuxostat; Gout; Gout Suppressants; Humans; Male; Middle Aged; Tendinopathy; Treatment Outcome; Ultrasonography	2020
HPRT-related hyperuricemia with a novel p.V35M mutation in HPRT1 presenting familial juvenile gout. CEN case reports, 2020, Volume: 9, Issue:3 Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Hypoxanthine Phosphoribosyltransferase; Kidney Calculi; Kidney Diseases; Male; Mutation, Missense; Treatment Outcome; Young Adult	2020
[Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)]. Der Internist, 2020, Volume: 61, Issue:5 Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Morbidity	2020
Febuxostat and atrial fibrillation. European heart journal, 2020, 08-07, Volume: 41, Issue:30 Topics: Aged; Allopurinol; Atrial Fibrillation; Febuxostat; Gout; Gout Suppressants; Humans; Medicare; United States	2020
The efficacy and tolerability of febuxostat treatment in a cohort of Chinese Han population with history of gout. The Journal of international medical research, 2020, Volume: 48, Issue:5 Topics: Adult; Asian People; China; Cohort Studies; Double-Blind Method; Ethnicity; Febuxostat; Female; Gout; Humans; Hyperuricemia; Interleukin-17; Interleukin-6; Male; Middle Aged; Placebos; Random Allocation; Treatment Outcome; Tumor Necrosis Factor-alpha; Uric Acid	2020
A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects. British journal of clinical pharmacology, 2020, Volume: 86, Issue:12 Topics: Adult; Febuxostat; Female; Gout; Gout Suppressants; Healthy Volunteers; Humans; Kidney; Male; Renal Elimination; Uric Acid; Young Adult	2020
2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis & rheumatology (Hoboken, N.J.), 2020, Volume: 72, Issue:6 Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Rheumatology; United States	2020
Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study. Clinical rheumatology, 2020, Volume: 39, Issue:12 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Middle Aged; Retrospective Studies; Uric Acid	2020
Underscoring the Importance of Allopurinol in Treating Gout: Results of a Food and Drug Administration-Mandated Safety Trial. Arthritis & rheumatology (Hoboken, N.J.), 2020, Volume: 72, Issue:6 Topics: Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration	2020
Response to: 'Correspondence to "Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data' by Ma Annals of the rheumatic diseases, 2022, Volume: 81, Issue:6 Topics: Aged; Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medicare; United States	2022
Confounding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'. Annals of the rheumatic diseases, 2022, Volume: 81, Issue:7 Topics: Aged; Allopurinol; Ethnicity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medicare; United States	2022
Response to: 'Confunding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'' by Hsu Annals of the rheumatic diseases, 2022, Volume: 81, Issue:7 Topics: Aged; Allopurinol; Ethnicity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medicare; United States	2022
Correspondence to 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'. Annals of the rheumatic diseases, 2022, Volume: 81, Issue:6 Topics: Aged; Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medicare; United States	2022
[Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy]. Terapevticheskii arkhiv, 2019, May-15, Volume: 91, Issue:5 Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Prevalence; Uric Acid	2019
Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout. Clinical rheumatology, 2021, Volume: 40, Issue:1 Topics: Allopurinol; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Retrospective Studies; Thailand; Thiazoles; Treatment Outcome; Uric Acid	2021
Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland. Annals of the rheumatic diseases, 2022, Volume: 81, Issue:7 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia	2022
Response to: 'Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland' by Quills Annals of the rheumatic diseases, 2022, Volume: 81, Issue:7 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Skin	2022
Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: a prospective observational study. Arthritis research & therapy, 2020, 07-11, Volume: 22, Issue:1 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Inflammation	2020
In older adults, new use of allopurinol or febuxostat was linked to hypersensitivity reactions versus colchicine. Annals of internal medicine, 2020, 07-21, Volume: 173, Issue:2 Topics: Aged; Allopurinol; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Medicare; United States	2020
Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines. Modern rheumatology, 2021, Volume: 31, Issue:3 Topics: Adult; Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Philippines; Treatment Outcome; Uric Acid	2021
To Switch or Not Switch Febuxostat: Comment on the Article by FitzGerald et al. Arthritis & rheumatology (Hoboken, N.J.), 2021, Volume: 73, Issue:2 Topics: Febuxostat; Gout; Gout Suppressants; Humans; Rheumatology; United States	2021
Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight. Clinical pharmacokinetics, 2021, Volume: 60, Issue:3 Topics: Body Weight; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male	2021
Trends in Utilization of Urate-Lowering Therapies Following the US Food and Drug Administration's Boxed Warning on Febuxostat. Arthritis & rheumatology (Hoboken, N.J.), 2021, Volume: 73, Issue:3 Topics: Allopurinol; Cardiovascular Diseases; Cause of Death; Drug Labeling; Febuxostat; Gout; Gout Suppressants; Humans; Mortality; Polyethylene Glycols; Practice Patterns, Physicians'; Probenecid; Risk Factors; Thioglycolates; Triazoles; United States; United States Food and Drug Administration; Urate Oxidase	2021
FAST: new look at the febuxostat safety profile. Lancet (London, England), 2020, 11-28, Volume: 396, Issue:10264 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Prospective Studies	2020
Febuxostat cardiovascular safety revisited. Nature reviews. Rheumatology, 2021, Volume: 17, Issue:1 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Prospective Studies	2021
Treatment of refractory gout with TNF-α antagonist etanercept combined with febuxostat. Annals of palliative medicine, 2020, Volume: 9, Issue:6 Topics: Etanercept; Febuxostat; Gout; Gout Suppressants; Humans; Male; Treatment Outcome; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha	2020
Combining Model-Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design. CPT: pharmacometrics & systems pharmacology, 2021, Volume: 10, Issue:1 Topics: Allopurinol; Bayes Theorem; Clinical Trials, Phase III as Topic; Computer Simulation; Decision Theory; Drug Development; Economics, Pharmaceutical; Febuxostat; Gout; Humans; Hyperuricemia; Investments; Models, Biological; Models, Economic; Reimbursement Mechanisms; Research Design; Sample Size; Uncertainty; Uric Acid	2021
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease　- Japanese Guideline on the Management of Asymptomatic Hyperuricemia. Circulation journal : official journal of the Japanese Circulation Society, 2021, 01-25, Volume: 85, Issue:2 Topics: Allopurinol; Cardiovascular Diseases; Endothelial Cells; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Risk Factors; Uric Acid	2021
Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial. Arthritis & rheumatology (Hoboken, N.J.), 2021, Volume: 73, Issue:5 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans	2021
[Gout]. Der Internist, 2021, Volume: 62, Issue:5 Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Symptom Flare Up; Uric Acid	2021
Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol. Journal of the American Heart Association, 2021, 04-06, Volume: 10, Issue:7 Topics: Aged; Allopurinol; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppressants; Humans; Incidence; Male; Retrospective Studies; Risk Assessment; Survival Rate; United States	2021
Comparative efficacy of low-dose versus regular-dose colchicine to prevent flares in gout patients initiated on urate-lowering therapies. Rheumatology (Oxford, England), 2021, 12-24, Volume: 61, Issue:1 Topics: Adult; Aged; Allopurinol; Cohort Studies; Colchicine; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Retrospective Studies; Symptom Flare Up	2021
Drastic monosodium urate crystal dissolution with febuxostat and benzbromarone. Joint bone spine, 2021, Volume: 88, Issue:4 Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Solubility; Uric Acid	2021
Ultrasound Evaluation of Three Outcome Domains in the Follow-up of Urate-Lowering Therapy in Gout: An Observational Study. Ultrasound in medicine & biology, 2021, Volume: 47, Issue:6 Topics: Adult; Arthritis; Bone Diseases; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Male; Middle Aged; Prospective Studies; Synovitis; Time Factors; Treatment Outcome; Ultrasonography; Uric Acid	2021
Formulation and Characterization of Febuxostat Loaded Nanostructured Lipid Carriers (NLCs) - Gel for Topical Treatment of Gout. Recent patents on nanotechnology, 2022, Volume: 16, Issue:3 Topics: Drug Carriers; Febuxostat; Gout; Humans; Hyperuricemia; Lipids; Nanostructures; Particle Size; Polymers	2022
[Cardiovascular risk in gout - Role of allopurinol?] Nederlands tijdschrift voor geneeskunde, 2021, 04-26, Volume: 165 Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Male; Risk Factors	2021
Management of Gout and Hyperuricemia in CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:3 Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Diet Therapy; Disease Management; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Symptom Flare Up; Treatment Outcome; Uric Acid	2017
Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy. Biological & pharmaceutical bulletin, 2017, Volume: 40, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Uric Acid	2017
Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data. Annals of the rheumatic diseases, 2017, Volume: 76, Issue:10 Topics: Administrative Claims, Healthcare; Aged; Aged, 80 and over; Allopurinol; Comparative Effectiveness Research; Febuxostat; Female; Gout; Gout Suppressants; Humans; Incidence; Kidney Diseases; Male; Medicare; Propensity Score; Proportional Hazards Models; Retrospective Studies; United States	2017
Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis. PharmacoEconomics, 2017, Volume: 35, Issue:10 Topics: Allopurinol; Cost-Benefit Analysis; Drug Administration Schedule; Febuxostat; Gout; Humans; Markov Chains; Models, Economic; Research Design	2017
Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database. The Korean journal of internal medicine, 2018, Volume: 33, Issue:1 Topics: Allopurinol; Benzbromarone; Databases, Factual; Febuxostat; Gout; Gout Suppressants; Humans; Republic of Korea; Uric Acid	2018
Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout. British journal of clinical pharmacology, 2018, Volume: 84, Issue:1 Topics: Computer Simulation; Drug Therapy, Combination; Febuxostat; Gout; Gout Suppressants; Humans; Male; Medication Adherence; Models, Biological; Risk Assessment; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid; Xanthine Oxidase	2018
Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease. BMJ case reports, 2018, Jan-31, Volume: 2018 Topics: Adult; Chronic Disease; Drug Therapy, Combination; Febuxostat; Foot Deformities, Acquired; Gout; Gout Suppressants; Humans; Male; Probenecid; Renal Insufficiency, Chronic; Severity of Illness Index; Treatment Outcome; Uric Acid	2018
Risk of Heart-Related Death From Gout Medication. The American journal of nursing, 2018, Volume: 118, Issue:3 Topics: Cardiovascular Diseases; Cause of Death; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; United States; United States Food and Drug Administration	2018
Any sleep is a dream far away: a nominal group study assessing how gout affects sleep. Rheumatology (Oxford, England), 2018, 11-01, Volume: 57, Issue:11 Topics: Aged; Allopurinol; Anxiety; Depression; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Sleep; Sleep Wake Disorders	2018
Chronic Disease Approaches Needed to Curb Gout's Growing Burden. JAMA, 2018, Apr-03, Volume: 319, Issue:13 Topics: Allopurinol; Chronic Disease; Diet; Drug Combinations; Febuxostat; Gout; Gout Suppressants; Healthy Lifestyle; Humans; Patient Education as Topic; Practice Guidelines as Topic; Purines; Thioglycolates; Triazoles; Uric Acid	2018
Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy. PharmacoEconomics, 2018, Volume: 36, Issue:5 Topics: Allopurinol; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Italy; Male; Markov Chains; Middle Aged; Models, Economic; Monte Carlo Method; Quality-Adjusted Life Years; Thioglycolates; Triazoles	2018
A retrospective investigation of HLA-B5801 in hyperuricemia patients in a Han population of China. Pharmacogenetics and genomics, 2018, Volume: 28, Issue:5* Topics: Adult; Allopurinol; China; Cost-Benefit Analysis; Febuxostat; Female; Gene Frequency; Genetic Testing; Gout; Gout Suppressants; HLA-B Antigens; Humans; Hyperuricemia; Male; Middle Aged; Precision Medicine; Retrospective Studies; Treatment Outcome	2018
Surprising safety outcomes of urate-lowering therapy. Nature reviews. Rheumatology, 2018, Volume: 14, Issue:6 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Uric Acid	2018
A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands. Clinical rheumatology, 2018, Volume: 37, Issue:8 Topics: Adult; Aged; Allopurinol; Benzbromarone; Febuxostat; Female; General Practitioners; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Medication Adherence; Middle Aged; Netherlands; Retrospective Studies; Rheumatologists; Uricosuric Agents; Young Adult	2018
Long-term adherence and persistence with febuxostat among male patients with gout in a routine clinical setting. Modern rheumatology, 2019, Volume: 29, Issue:4 Topics: Adult; Aged; Febuxostat; Gout; Gout Suppressants; Humans; Male; Medication Adherence; Middle Aged	2019
New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. Arthritis & rheumatology (Hoboken, N.J.), 2018, Volume: 70, Issue:11 Topics: Allopurinol; Cardiovascular Diseases; Comorbidity; Enzyme Inhibitors; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Mortality; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Xanthine Oxidase	2018
[Design, synthesis and biological evaluation of oxadiazole derivatives as xanthine oxidase inhibitors]. Yao xue xue bao = Acta pharmaceutica Sinica, 2016, Volume: 51, Issue:6 Topics: Drug Design; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Oxadiazoles; Xanthine Oxidase	2016
Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study. Circulation, 2018, 09-11, Volume: 138, Issue:11 Topics: Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Cause of Death; Databases, Factual; Febuxostat; Female; Gout; Hospitalization; Humans; Hyperuricemia; Male; Medicare; Protective Factors; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States	2018
Febuxostat for the treatment of hyperuricaemia in gout. Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:11 Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia	2018
Goals of gout treatment: a patient perspective. Clinical rheumatology, 2018, Volume: 37, Issue:9 Topics: Allopurinol; Febuxostat; Female; Goals; Gout; Gout Suppressants; Humans; Life Style; Male; Middle Aged; Patient Education as Topic; Symptom Flare Up	2018
Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study. Clinical rheumatology, 2018, Volume: 37, Issue:11 Topics: Aged; Arthritis, Gouty; Creatinine; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Uric Acid	2018
Fresh Perspectives on the CARES Trial and the Use of Febuxostat in an Asian Population: Comment on the Article by Choi et al. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:3 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Rheumatology; United States Food and Drug Administration	2019
Febuxostat Does Not Increase All-Cause Mortality and Cardiovascular Mortality Compared With Placebo: Comment on the Article by Choi et al. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:3 Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Rheumatology; United States Food and Drug Administration	2019
Reply. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:3 Topics: Allopurinol; Febuxostat; Gout; Humans; Rheumatology; United States; United States Food and Drug Administration	2019
Cardiovascular Safety of Febuxostat. The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16 Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid	2018
Cardiovascular Safety of Febuxostat. The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16 Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid	2018
Cardiovascular Safety of Febuxostat. The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16 Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid	2018
Cardiovascular Safety of Febuxostat. The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16 Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid	2018
Gout, Xanthine Oxidase Inhibition, and Cardiovascular Outcomes. Circulation, 2018, 09-11, Volume: 138, Issue:11 Topics: Aged; Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Risk Factors; Xanthine Oxidase	2018
Hepatic Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease. The Journal of rheumatology, 2019, Volume: 46, Issue:5 Topics: Adult; Allopurinol; Analysis of Variance; Cohort Studies; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Liver; Febuxostat; Female; Gout; Gout Suppressants; Humans; Liver; Liver Function Tests; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Risk Assessment; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Doppler	2019
Urate-Lowering Therapy for Preventing Kidney Disease Progression: Are We There Yet? American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018, Volume: 72, Issue:6 Topics: Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid	2018
Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2018, Volume: 21, Issue:12 Topics: Allopurinol; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Economics, Pharmaceutical; Febuxostat; Gout; Gout Suppressants; Health Care Costs; Humans; Medication Adherence; Models, Biological; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Thioglycolates; Treatment Outcome; Triazoles; United Kingdom; Uric Acid	2018
Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation. Clinical rheumatology, 2019, Volume: 38, Issue:1 Topics: Allopurinol; Cardiovascular Diseases; Cause of Death; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Randomized Controlled Trials as Topic; Risk Factors	2019
Gout and the risk of incident depression in older adults. Psychiatry research, 2018, Volume: 270 Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Comorbidity; Depressive Disorder; Febuxostat; Female; Follow-Up Studies; Gout; Humans; Incidence; Male; Mass Screening; Medicare; Proportional Hazards Models; Retrospective Studies; Risk; United States	2018
[A case of gout secondary to primary myelofibrosis]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2018, Dec-18, Volume: 50, Issue:6 Topics: Arthritis, Gouty; Febuxostat; Gout; Gout Suppressants; Humans; Male; Middle Aged; Primary Myelofibrosis; Uric Acid	2018
No association between ATP-binding cassette transporter G2 rs2231142 (Q141K) and urate-lowering response to febuxostat. Rheumatology (Oxford, England), 2019, 03-01, Volume: 58, Issue:3 Topics: Adult; Aged; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; Febuxostat; Female; Genotype; Gout; Gout Suppressants; Humans; Male; Middle Aged; Neoplasm Proteins; Pharmacogenetics; Polymorphism, Single Nucleotide; Treatment Outcome	2019
Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Surveys; Prevalence; Probenecid; United States; Uric Acid; Uricosuric Agents; Young Adult	2019
Limitations in Assessing Cardiovascular Risk of Febuxostat in Patients With Gout and Cardiovascular Morbidities: Comment on the Article by Choi et al. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:6 Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Rheumatology; Risk Factors; United States Food and Drug Administration	2019
Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real-world patients: A nationwide study. International journal of clinical practice, 2019, Volume: 73, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Child; Child, Preschool; Cohort Studies; Drug Eruptions; Febuxostat; Female; Gout; Gout Suppressants; Humans; Infant; Infant, Newborn; Interrupted Time Series Analysis; Male; Middle Aged; Retrospective Studies; Risk Factors; Taiwan; Young Adult	2019
Letter by Kuwabara Regarding Article, "Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study". Circulation, 2019, 03-05, Volume: 139, Issue:10 Topics: Aged; Allopurinol; Cardiovascular Diseases; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans; Patients; Population; Risk Factors	2019
Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update. Cardiology journal, 2019, Volume: 26, Issue:1 Topics: Aged; Allopurinol; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Uric Acid; Xanthine Oxidase	2019
The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients. Arthritis research & therapy, 2019, 03-20, Volume: 21, Issue:1 Topics: Adolescent; Adult; Allopurinol; ATP Binding Cassette Transporter, Subfamily G, Member 2; Child; Child, Preschool; Cohort Studies; Czech Republic; Febuxostat; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Young Adult	2019
Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data. European heart journal, 2019, 09-21, Volume: 40, Issue:36 Topics: Aged; Allopurinol; Atrial Fibrillation; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Medicare; United States	2019
Gout and chronic pain in older adults: a Medicare claims study. Clinical rheumatology, 2019, Volume: 38, Issue:7 Topics: Aged; Aged, 80 and over; Allopurinol; Chronic Pain; Comorbidity; Febuxostat; Female; Gout; Humans; Incidence; Male; Medicare; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; United States	2019
Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis. The Korean journal of internal medicine, 2020, Volume: 35, Issue:4 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Renal Insufficiency, Chronic; Republic of Korea; Treatment Outcome; Uric Acid	2020
Integration of Pharmacometrics and Pharmacoeconomics to Quantify the Value of Improved Forgiveness to Nonadherence: A Case Study of Novel Xanthine Oxidase Inhibitors for Gout. Clinical pharmacology and therapeutics, 2019, Volume: 106, Issue:3 Topics: Allopurinol; Computer Simulation; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Monitoring; Economics, Pharmaceutical; Febuxostat; Gout; Gout Suppressants; Humans; Insurance, Health, Reimbursement; Medication Adherence; Quality-Adjusted Life Years; Uric Acid; Xanthine Oxidase	2019
Excess Deaths Upon Cessation of Xanthine Oxidase Inhibitor Treatment-Data From the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial: Comment on the Article by Choi et al. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:8 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Rheumatology; United States Food and Drug Administration; Xanthine Oxidase	2019
Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. Rheumatology (Oxford, England), 2019, 12-01, Volume: 58, Issue:12 Topics: Aged; Allopurinol; Cardiovascular Diseases; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Humans; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Proportional Hazards Models; Republic of Korea; Stroke	2019
Gout Medication Receives Black Box Warning. The American journal of nursing, 2019, Volume: 119, Issue:6 Topics: Drug Labeling; Febuxostat; Gout; Gout Suppressants; Humans; United States; United States Food and Drug Administration	2019
Cardiovascular Safety of Febuxostat Versus Allopurinol in the Real World: Old Reliable Comes Out on Top. Mayo Clinic proceedings, 2019, Volume: 94, Issue:7 Topics: Allopurinol; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans	2019
Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study. Mayo Clinic proceedings, 2019, Volume: 94, Issue:7 Topics: Aged; Allopurinol; Cardiovascular Diseases; Databases, Factual; Febuxostat; Female; Gout; Gout Suppressants; Hospitalization; Humans; Male; Retrospective Studies; Risk Factors; Taiwan	2019
Febuxostat Desensitization in a Patient with Previous Stevens-Johnson Syndrome and The Journal of rheumatology, 2019, Volume: 46, Issue:9 Topics: Adult; Febuxostat; Genotype; Gout; HLA-B Antigens; Humans; Male; Stevens-Johnson Syndrome	2019
Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients. International journal of rheumatic diseases, 2019, Volume: 22, Issue:8 Topics: Adult; Allopurinol; Benzbromarone; Biomarkers; Cholesterol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hypercholesterolemia; Hypertriglyceridemia; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Triglycerides; Uric Acid; Uricosuric Agents	2019
Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits. Arthritis & rheumatology (Hoboken, N.J.), 2020, Volume: 72, Issue:1 Topics: Aged; Alcohol Drinking; Allopurinol; Benzbromarone; Diet Therapy; Febuxostat; Female; Foot Joints; Fructose; Gout; Gout Suppressants; Humans; Male; Meat; Middle Aged; Prospective Studies; Purines; Shellfish; Tomography, X-Ray Computed; Uric Acid; Uricosuric Agents	2020
Xanthine Oxidase Inhibitor Withdrawal Syndrome? Comment on the Article by Choi et al. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:11 Topics: Allopurinol; Febuxostat; Gout; Humans; Rheumatology; United States; United States Food and Drug Administration; Xanthine Oxidase	2019
Reply. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:11 Topics: Allopurinol; Febuxostat; Gout; Humans; Rheumatology; United States; United States Food and Drug Administration	2019
Italian Society of Rheumatology recommendations for the management of gout. Reumatismo, 2013, Mar-28, Volume: 65, Issue:1 Topics: Adrenal Cortex Hormones; Advisory Committees; Alcoholic Beverages; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Combined Modality Therapy; Dairy Products; Disease Management; Evidence-Based Medicine; Febuxostat; Female; Fructose; Gout; Humans; Italy; Male; Risk Factors; Smoking; Societies, Medical; Thiazoles; Uric Acid	2013
Cost-effectiveness of febuxostat in chronic gout. The European journal of health economics : HEPAC : health economics in prevention and care, 2014, Volume: 15, Issue:5 Topics: Cost-Benefit Analysis; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Reproducibility of Results; Thiazoles; Uric Acid	2014
Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. Arthritis care & research, 2013, Volume: 65, Issue:12 Topics: Allopurinol; Ambulatory Care; Colchicine; Comorbidity; Febuxostat; Female; Gout; Gout Suppressants; Hospitalization; Humans; Male; Middle Aged; Office Visits; Thiazoles	2013
Irregular gout. International journal of rheumatic diseases, 2014, Volume: 17, Issue:3 Topics: Chelating Agents; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Lead Poisoning; Male; Occupational Diseases; Occupational Exposure; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome; Young Adult	2014
CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts. The American journal of medicine, 2014, Volume: 127, Issue:1 Topics: Allopurinol; Comorbidity; Disease Management; Drug Administration Schedule; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medication Adherence; Primary Health Care; Risk Factors; Severity of Illness Index; Thiazoles; United States; Uric Acid	2014
Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease. Journal of clinical pharmacy and therapeutics, 2014, Volume: 39, Issue:3 Topics: Aged; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Renal Insufficiency, Chronic; Rhabdomyolysis; Thiazoles	2014
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study. Arthritis research & therapy, 2014, Mar-29, Volume: 16, Issue:2 Topics: Aged; Allopurinol; Black or African American; Evaluation Studies as Topic; Febuxostat; Female; Focus Groups; Gout; Gout Suppressants; Health Knowledge, Attitudes, Practice; Humans; Male; Medication Adherence; Middle Aged; Thiazoles; Uric Acid	2014
Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. Postgraduate medicine, 2014, Volume: 126, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Biomarkers; Comparative Effectiveness Research; Drug Administration Schedule; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Logistic Models; Male; Middle Aged; Retrospective Studies; Thiazoles; Treatment Outcome; Uric Acid; Young Adult	2014
Prevalence of treatment of hyperuricemic in patients admitted to the rheumatology ward and evaluation of compliance with the 2012 ACR Guidelines. Joint bone spine, 2014, Volume: 81, Issue:5 Topics: Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Guideline Adherence; Hospitalization; Humans; Hyperuricemia; Male; Prevalence; Thiazoles; Xanthine Oxidase	2014
Anakinra treatment in patients with gout and type 2 diabetes. Clinical rheumatology, 2015, Volume: 34, Issue:5 Topics: Aged; Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Blood Glucose; Carbamates; Colchicine; Diabetes Mellitus, Type 2; Febuxostat; Glycated Hemoglobin; Gout; Gout Suppressants; Humans; Hyperuricemia; Hypoglycemic Agents; Insulin; Interleukin 1 Receptor Antagonist Protein; Metformin; Middle Aged; Piperidines; Treatment Outcome; Uric Acid	2015
Treat to target in gout by combining two modes of action. Rheumatology (Oxford, England), 2014, Volume: 53, Issue:12 Topics: Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Thiazoles; Thioglycolates; Triazoles	2014
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. Journal of Korean medical science, 2014, Volume: 29, Issue:5 Topics: Adult; Allopurinol; Antimetabolites; Benzbromarone; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hypertension; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Uric Acid; Uricosuric Agents; Urolithiasis	2014
Efficacy and safety of febuxostat in elderly female patients. Clinical interventions in aging, 2014, Volume: 9 Topics: Aged; Comorbidity; Febuxostat; Female; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Retrospective Studies; Thiazoles; Treatment Outcome	2014
Can febuxostat reduce triglyceride and cholesterol serum levels in gouty patients? Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2014, Volume: 20, Issue:7 Topics: Aged; Cholesterol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Thiazoles; Triglycerides	2014
Cost-effectiveness of allopurinol and febuxostat for the management of gout. Annals of internal medicine, 2014, Nov-04, Volume: 161, Issue:9 Topics: Allopurinol; Cost Savings; Cost-Benefit Analysis; Drug Therapy, Combination; Febuxostat; Gout; Gout Suppressants; Humans; Markov Chains; Models, Theoretical; Quality-Adjusted Life Years; Thiazoles	2014
Adherence and persistence to urate-lowering therapies in the Irish setting. Clinical rheumatology, 2016, Volume: 35, Issue:3 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Databases, Factual; Febuxostat; Female; Gout; Gout Suppressants; Humans; Ireland; Male; Medication Adherence; Middle Aged; Retrospective Studies; Sex Factors; Uric Acid; Young Adult	2016
Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective. Journal of managed care & specialty pharmacy, 2015, Volume: 21, Issue:2 Topics: Allopurinol; Chronic Disease; Cost-Benefit Analysis; Febuxostat; Gout; Gout Suppressants; Humans; Markov Chains; Thiazoles; Uric Acid	2015
Characteristics and management of gout patients in Europe: data from a large cohort of patients. European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:4 Topics: Adult; Allopurinol; Cohort Studies; Comorbidity; Cross-Sectional Studies; Europe; Febuxostat; Female; France; Gout; Gout Suppressants; Greece; Humans; Male; Middle Aged; Obesity; Patient Compliance; Thiazoles; Uric Acid	2015
Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis research & therapy, 2015, May-12, Volume: 17 Topics: Aged; Allopurinol; Cohort Studies; Cost-Benefit Analysis; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Managed Care Programs; Medicare; Reference Values; Retrospective Studies; Severity of Illness Index; Treatment Outcome; United States; Uric Acid	2015
Gout: Why compare the effectiveness of suboptimal gout management? Nature reviews. Rheumatology, 2015, Volume: 11, Issue:9 Topics: Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male	2015
Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase. Rheumatology international, 2015, Volume: 35, Issue:11 Topics: Aged; Allopurinol; Biomarkers; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Thyrotropin; Time Factors; Treatment Outcome; Up-Regulation; Uric Acid; Xanthine Dehydrogenase	2015
Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS). Journal of clinical pharmacy and therapeutics, 2015, Volume: 40, Issue:6 Topics: Aged, 80 and over; Drug Hypersensitivity Syndrome; Eosinophilia; Febuxostat; Gout; Humans; Male	2015
Febuxostat in the management of gout: a cost-effectiveness analysis. Journal of medical economics, 2016, Volume: 19, Issue:3 Topics: Adult; Aged; Allopurinol; Cost-Benefit Analysis; Disease Management; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; United States; Uric Acid	2016
A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2015, Volume: 21, Issue:8 Topics: Adult; Aged; Allopurinol; Comparative Effectiveness Research; Drug Monitoring; Drug Substitution; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome; United States; Uric Acid; Xanthine Oxidase	2015
Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint bone spine, 2016, Volume: 83, Issue:3 Topics: Aged; Allopurinol; Drug Eruptions; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Retrospective Studies	2016
Cost-effectiveness analysis of febuxostat in patients with gout in Spain. Journal of medical economics, 2016, Volume: 19, Issue:6 Topics: Allopurinol; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Markov Chains; Models, Econometric; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Renal Insufficiency; Spain	2016
Giant gouty tophi in the hands. The lancet. Diabetes & endocrinology, 2017, Volume: 5, Issue:2 Topics: Febuxostat; Gout; Gout Suppressants; Hand; Humans; Male; Middle Aged; Treatment Outcome	2017
[Using the whole arsenal to prevent an attack]. MMW Fortschritte der Medizin, 2015, Nov-19, Volume: 157, Issue:20 Topics: Allopurinol; Arthritis, Gouty; Benzbromarone; Combined Modality Therapy; Febuxostat; Female; Gout; Gout Suppressants; Humans; Middle Aged; Polyethylene Glycols; Urate Oxidase	2015
[Drug reduction of uric acid not just when symptoms appear]. MMW Fortschritte der Medizin, 2016, Mar-17, Volume: 158, Issue:5 Topics: Allopurinol; Clinical Trials as Topic; Febuxostat; Gout; Humans; Hyperuricemia; Uric Acid	2016
Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease. Journal of managed care & specialty pharmacy, 2016, Volume: 22, Issue:4 Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Cost-Benefit Analysis; Febuxostat; Female; Gout; Gout Suppressants; Health Care Costs; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Uric Acid	2016
Febuxostat for Asymptomatic Hyperuricemia in CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2016, Volume: 67, Issue:6 Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid; Xanthine Oxidase	2016
Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2016, Volume: 67, Issue:6 Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid	2016
In Reply to 'Febuxostat for Asymptomatic Hyperuricemia in CKD' and 'Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia'. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2016, Volume: 67, Issue:6 Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid	2016
The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective. Clinical therapeutics, 2016, Volume: 38, Issue:7 Topics: Adult; Aged; Allopurinol; Budgets; Chronic Disease; Febuxostat; Female; Gout; Gout Suppressants; Health Care Costs; Humans; Male; Managed Care Programs; Middle Aged; Pharmaceutical Services; Renal Insufficiency, Chronic; United States; Uric Acid; Young Adult	2016
Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al. Arthritis & rheumatology (Hoboken, N.J.), 2016, Volume: 68, Issue:10 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid	2016
Tophaceous Gout in an Anorectic Patient Visualized by Dual Energy Computed Tomography (DECT). The American journal of case reports, 2016, Jul-15, Volume: 17 Topics: Absorptiometry, Photon; Allopurinol; Anorexia Nervosa; Biomarkers; Biopsy; Colchicine; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Middle Aged; Patient Compliance; Predictive Value of Tests; Sensitivity and Specificity; Urate Oxidase; Uric Acid	2016
Digital Tophaceous Gout. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2016, Volume: 22, Issue:6 Topics: Allopurinol; Drug Costs; Febuxostat; Fingers; Gout; Gout Suppressants; Health Equity; Humans; Male; Middle Aged; Symptom Flare Up	2016
Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose. Rheumatology international, 2017, Volume: 37, Issue:3 Topics: Acute Disease; Aged; Allopurinol; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Uric Acid; Xanthine Oxidase	2017
Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint bone spine, 2017, Volume: 84, Issue:5 Topics: Academic Medical Centers; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Comorbidity; Febuxostat; Female; Follow-Up Studies; France; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Incidence; Male; Middle Aged; Patient Safety; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Sex Factors; Statistics, Nonparametric; Survival Rate; Treatment Outcome	2017
Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout. Rheumatology international, 2017, Volume: 37, Issue:2 Topics: Adult; Aged; C-Reactive Protein; Febuxostat; Female; Gout; Gout Suppressants; Humans; Insulin Resistance; Male; Middle Aged; Uric Acid; Young Adult	2017
Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout. The Annals of pharmacotherapy, 2017, Volume: 51, Issue:4 Topics: Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Drug Monitoring; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Retrospective Studies; Rheumatology; Tennessee; Uric Acid; Veterans; Xanthine Oxidase	2017
A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study . International journal of clinical pharmacology and therapeutics, 2017, Volume: 55, Issue:2 Topics: Adult; Allopurinol; Asian People; Benzbromarone; Biomarkers; China; Drug Dosage Calculations; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome; Uric Acid	2017
The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012. Seminars in arthritis and rheumatism, 2017, Volume: 46, Issue:4 Topics: Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; British Columbia; Colchicine; Comorbidity; Diabetes Mellitus; Febuxostat; Female; Glucocorticoids; Gout; Gout Suppressants; Humans; Hyperlipidemias; Hypertension; Incidence; Male; Middle Aged; Population Growth; Prevalence; Probenecid; Sulfinpyrazone; Uricosuric Agents	2017
Febuxostat-induced agranulocytosis in an end-stage renal disease patient: A case report. Medicine, 2017, Volume: 96, Issue:2 Topics: Aged; Agranulocytosis; Febuxostat; Female; Gout; Gout Suppressants; Humans; Kidney Failure, Chronic	2017
Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice. International journal of rheumatic diseases, 2017, Volume: 20, Issue:7 Topics: Aged; Allopurinol; Biomarkers; Drug Substitution; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Medical Audit; Medication Adherence; Practice Guidelines as Topic; Probenecid; Retrospective Studies; Rheumatology; Time Factors; Treatment Outcome; Uric Acid	2017
Advances in Urate-Lowering Therapy: Time to Revisit High-Dose Febuxostat. American journal of therapeutics, 2017, Volume: 24, Issue:3 Topics: Drug Approval; Drug Therapy, Combination; Febuxostat; Gout; Gout Suppressants; Humans; United States; United States Food and Drug Administration	2017
Febuxostat: a viewpoint by H. Ralph Schumacher Jr and Lan X. Chen. Drugs, 2008, Volume: 68, Issue:13 Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid	2008
Febuxostat : a viewpoint by Naomi Schlesinger. Drugs, 2008, Volume: 68, Issue:13 Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid	2008
Febuxostat : a viewpoint by N. Lawrence Edwards. Drugs, 2008, Volume: 68, Issue:13 Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid	2008
Gout management: let's get it right this time. Arthritis and rheumatism, 2008, Nov-15, Volume: 59, Issue:11 Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Drug Evaluation; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Uric Acid; Xanthine Oxidase	2008
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. The Journal of rheumatology, 2009, Volume: 36, Issue:6 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Hyperuricemia; Thiazoles; Treatment Outcome; Uric Acid	2009
New gout treatment approved. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2009, Apr-01, Volume: 66, Issue:7 Topics: Administration, Oral; Drug Approval; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; United States; United States Food and Drug Administration; Uric Acid; Xanthine Oxidase	2009
Gout Study Group: update on hyperuricemia and gout. Joint bone spine, 2009, Volume: 76, Issue:4 Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diet; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Life Style; Prednisone; Prevalence; Thiazoles; United States; Uric Acid	2009
Febuxostat: new drug. Hyperuricaemia: risk of gout attacks. Prescrire international, 2009, Volume: 18, Issue:100 Topics: Allopurinol; Drug Approval; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles	2009
Febuxostat provides new gout treatment option. The Nurse practitioner, 2010, Volume: 35, Issue:3 Topics: Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles	2010
Febuxostat for gout. Drug and therapeutics bulletin, 2010, Volume: 48, Issue:7 Topics: Aged; Drug Costs; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Thiazoles	2010
The current state of care in gout: Addressing the need for better understanding of an ancient disease. Journal of the American Academy of Nurse Practitioners, 2010, Volume: 22 Suppl 1 Topics: Acute Disease; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Chronic Disease; Colchicine; Comorbidity; Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Patient Education as Topic; Quality of Life; Risk Factors; Thiazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase	2010
[Therapy of acute gout attack. It need not always be NSAID]. MMW Fortschritte der Medizin, 2010, Nov-25, Volume: 152, Issue:47 Topics: Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles	2010
Treatment of gout. Internal medicine journal, 2011, Volume: 41, Issue:1a Topics: Aged; Allopurinol; Australia; Colchicine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Febuxostat; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Kidney Diseases; Male; Patient Compliance; Practice Guidelines as Topic; Prednisolone; Renal Dialysis; Thiazoles; Uric Acid	2011
Febuxostat efficacy in allopurinol-resistant tophaceous gout. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:4 Topics: Allopurinol; Dose-Response Relationship, Drug; Drug Resistance; Febuxostat; Female; Gout; Gout Suppressants; Humans; Thiazoles; Treatment Failure; Treatment Outcome; Uric Acid; Young Adult	2011
Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. The Journal of rheumatology, 2011, Volume: 38, Issue:9 Topics: Aged; Aged, 80 and over; Allopurinol; Drug Monitoring; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Thiazoles; Uric Acid	2011
Gout and transplantation: new treatment option-same old drug interaction. Transplantation, 2011, Aug-15, Volume: 92, Issue:3 Topics: Aged; Azathioprine; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Thiazoles	2011
Catastrophic axial gout causing paraplegia in a patient with glycogen storage disease. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:7 Topics: Adult; Catastrophic Illness; Drug Therapy, Combination; Febuxostat; Glycogen Storage Disease Type I; Gout; Gout Suppressants; Humans; Magnetic Resonance Imaging; Male; Obesity, Morbid; Paraplegia; Prednisone; Probenecid; Radiography; Synovial Fluid; Thiazoles; Uric Acid	2011
Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout. Evidence-based medicine, 2012, Volume: 17, Issue:4 Topics: Allopurinol; Clinical Trials as Topic; Comparative Effectiveness Research; Cost-Benefit Analysis; Decision Making; Decision Trees; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles	2012
Febuxostat hypersensitivity. The Journal of rheumatology, 2012, Volume: 39, Issue:3 Topics: Aged; Drug Hypersensitivity; Erythema; Fatigue; Febuxostat; Female; Gout; Gout Suppressants; Humans; Pruritus; Thiazoles; Withholding Treatment	2012
Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid. The Medical journal of Malaysia, 2012, Volume: 67, Issue:1 Topics: Allopurinol; Chronic Disease; Contraindications; Febuxostat; Gout; Gout Suppressants; Humans; Male; Middle Aged; Probenecid; Thiazoles	2012
[Medication of the month. Febuxostat (Adenuric)]. Revue medicale de Liege, 2012, Volume: 67, Issue:4 Topics: Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles	2012
Casebook consults: improving outcomes in gout (multimedia activity). The American journal of medicine, 2012, Volume: 125, Issue:8 Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Long-Term Care; Medication Adherence; Referral and Consultation; Thiazoles; Uric Acid	2012
Adherence to uric acid treatment guidelines in a rheumatology clinic. Clinical rheumatology, 2012, Volume: 31, Issue:12 Topics: Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Guideline Adherence; Humans; Male; Middle Aged; Probenecid; Retrospective Studies; Thiazoles; Treatment Outcome; Uric Acid	2012
Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules. Inflammation & allergy drug targets, 2013, Volume: 12, Issue:1 Topics: Allopurinol; Animals; Desensitization, Immunologic; Drug Hypersensitivity; Febuxostat; Gout; Humans; Hyperuricemia; Product Surveillance, Postmarketing; Recombinant Proteins; Skin; Thiazoles; Urate Oxidase	2013
Febuxostat (Teijin/Ipsen/TAP). Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:11 Topics: Animals; Drug Evaluation, Preclinical; Enzyme Inhibitors; Febuxostat; Gout; Humans; Patents as Topic; Randomized Controlled Trials as Topic; Structure-Activity Relationship; Thiazoles; Xanthine Oxidase	2005
Febuxostat--treatment for hyperuricemia and gout? The New England journal of medicine, 2005, Dec-08, Volume: 353, Issue:23 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thiazoles; Uric Acid; Xanthine Oxidase	2005
Febuxostat versus allopurinol for gout. The New England journal of medicine, 2006, Apr-06, Volume: 354, Issue:14 Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Treatment Refusal; Xanthine Oxidase	2006
Febuxostat versus allopurinol for gout. The New England journal of medicine, 2006, Apr-06, Volume: 354, Issue:14 Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Treatment Refusal; Xanthine Oxidase	2006
Gout's not just for the gluttonous. The Johns Hopkins medical letter health after 50, 2006, Volume: 18, Issue:4 Topics: Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Risk Factors; Sex Factors; Socioeconomic Factors; Thiazoles; Uric Acid	2006
[Febuxostat versus allopurinol for hyperuricemia]. Medizinische Monatsschrift fur Pharmazeuten, 2006, Volume: 29, Issue:10 Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles	2006
Determination of plasma purine nucleoside phosphorylase activity by high-performance liquid chromatography. Analytical biochemistry, 1995, May-01, Volume: 227, Issue:1 Topics: Adult; Aged; Asthma; Calibration; Chromatography, High Pressure Liquid; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hypoxanthine; Hypoxanthines; Inosine; Male; Middle Aged; Purine-Nucleoside Phosphorylase; Thiazoles; Uric Acid; Xanthine Oxidase	1995
Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. European journal of pharmacology, 1993, Dec-21, Volume: 250, Issue:3 Topics: Administration, Oral; Allopurinol; Animals; Dose-Response Relationship, Drug; Febuxostat; Female; Gout; Macaca mulatta; Male; Pan troglodytes; Thiazoles; Uric Acid; Xanthine; Xanthine Oxidase; Xanthines	1993